

[19] Patents Registry [11] 1246681 B  
The Hong Kong Special Administrative Region  
香港特別行政區  
專利註冊處

[12] **STANDARD PATENT (R) SPECIFICATION**  
**轉錄標準專利說明書**

[21] Application no. 申請編號 [51] Int. Cl.  
18106307.5 A61K 35/74 (2015.01) A61K 9/00 (2006.01)  
[22] Date of filing 提交日期 A61K 9/19 (2006.01) A61K 9/48 (2006.01)  
15.05.2018 A23L 33/135 (2016.01) A61P 1/10 (2006.01)  
A61P 1/12 (2006.01) A61P 31/04 (2006.01)

---

[54] COMPOSITIONS COMPRISING A BACTERIAL STRAIN OF BLAUTIA HYDROGENOTROPHICA FOR USE IN THE  
TREATMENT OF BACTERIAL INFECTIONS OF THE GASTROINTESTINAL TRACT  
用於治療胃腸道細菌感染、包含 BLAUTIA HYDROGENOTROPHICA 的細菌菌株的組合物

[60] Divisional application no.& receipt date 分開申請編號及收 件日期 19133513.2 12.12.2019	[73] Proprietor 專利所有人 4D PHARMA PLC 5th floor, 9 Bond Court Leeds LS1 2JZ UNITED KINGDOM
[30] Priority 優先權 13.07.2016 GB 1612190.7 20.09.2016 GB 1616018.6 20.09.2016 GB 1616016.0 06.03.2017 GB 1703548.6 06.03.2017 GB 1703552.8	[72] Inventor 發明人 CROUZET, Laureen HABOUZIT, Chloe BERNALIER-DONADILLE, Annick
[43] Date of publication of application 申請發表日期 14.09.2018	[74] Agent and / or address for service 代理人及/或送達地址 DEACONS 5th Floor, Alexandra House Central HONG KONG
[45] Date of publication of grant of patent 批予專利的發表日期 20.03.2020	
[86] International application no. 國際申請編號 PCT/GB2017/052076	
[87] International publication no. and date 國際申請發表編號及 日期 WO2018/011593 18.01.2018 EP Application no. & date 歐洲專利申請編號及日期 EP 17742523.8 13.07.2017 EP Publication no. & date 歐洲專利申請發表編號及日期 EP 3313421 02.05.2018 Date of grant in designated patent office 指定專利當局批予專利日 期 06.03.2019	



(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:

06.03.2019 Bulletin 2019/10

(21) Application number: 17742523.8

(22) Date of filing: 13.07.2017

(51) Int Cl.:

**A61K 35/74** (2015.01) **A61K 9/00** (2006.01)  
**A61K 9/19** (2006.01) **A61K 9/48** (2006.01)  
**A23L 33/135** (2016.01) **A61P 1/10** (2006.01)  
**A61P 1/12** (2006.01) **A61P 31/04** (2006.01)

(86) International application number:  
PCT/GB2017/052076(87) International publication number:  
WO 2018/011593 (18.01.2018 Gazette 2018/03)(54) **COMPOSITIONS COMPRISING A BACTERIAL STRAIN OF BLAUTIA HYDROGENOTROPHICA FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS OF THE GASTROINTESTINAL TRACT**

ZUSAMMENSETZUNGEN ENTHALTEND EINEN BAKTERIENSTAMM VON BLAUTIA HYDROGENOTROPHICA ZUR VERWENDUNG ZUR BEHANDLUNG VON BAKTERIELLEN INFektIONEN DES MAGEN-DARM-TRAKTES

COMPOSITIONS COMPRENANT UNE SOUCHES BACTÉRIENNE DE BLAUTIA HYDROGENOTROPHICA POUR L'UTILISATION POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES DU TRACTUS GASTRO-INTESTINAL

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR

Designated Extension States:

BA ME

Designated Validation States:

MA MD

(30) Priority: 13.07.2016 GB 201612190

20.09.2016 GB 201616018

20.09.2016 GB 201616016

06.03.2017 GB 201703548

06.03.2017 GB 201703552

(43) Date of publication of application:

02.05.2018 Bulletin 2018/18

(73) Proprietor: 4D PHARMA PLC

Leeds, LS1 2JZ (GB)

(72) Inventors:

• CROUZET, Laureen

Leeds LS1 2JZ (GB)

• HABOUZIT, Chloe

63400 Chamaliere (FR)

- **BERNALIER-DONADILLE, Annick**  
63670 La Roche Blanc (FR)

(74) Representative: **Marshall, Cameron John**  
Carpmaels & Ransford LLP  
One Southampton Row  
London WC1B 5HA (GB)

(56) References cited:

<b>WO-A1-01/85187</b>	<b>WO-A1-02/07741</b>
<b>WO-A1-2012/142605</b>	<b>WO-A1-2016/057671</b>
US-A1- 2010 247 489	US-A1- 2016 184 370

- C. LIU ET AL: "Reclassification of *Clostridium coccoides*, *Ruminococcus hansenii*, *Ruminococcus hydrogenotrophicus*, *Ruminococcus luti*, *Ruminococcus productus* and *Ruminococcus schinkii* as *Blautia coccoides* gen. nov., comb. nov., *Blautia hansenii* comb. nov., *Blautia luti* comb. nov", INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, vol. 58, no. 8, 1 August 2008 (2008-08-01), pages 1896-1902, XP055005236, ISSN: 1466-5026, DOI: 10.1099/ij.s.0.65208-0

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description****TECHNICAL FIELD**

5 [0001] This invention is in the field of compositions comprising bacterial strains isolated from the mammalian digestive tract and the use of such compositions in the treatment of disease, as defined in the claims.

**BACKGROUND TO THE INVENTION**

10 [0002] The human intestine is thought to be sterile *in utero*, but it is exposed to a large variety of maternal and environmental microbes immediately after birth. Thereafter, a dynamic period of microbial colonization and succession occurs, which is influenced by factors such as delivery mode, environment, diet and host genotype, all of which impact upon the composition of the gut microbiota, particularly during early life. Subsequently, the microbiota stabilizes and becomes adult-like [i]. The human gut microbiota contains more than 1500 different phylotypes dominated in abundance 15 levels by two major bacterial divisions (*phyla*), the Bacteroidetes and the Firmicutes [ii-iii]. The successful symbiotic relationships arising from bacterial colonization of the human gut have yielded a wide variety of metabolic, structural, protective and other beneficial functions. The enhanced metabolic activities of the colonized gut ensure that otherwise indigestible dietary components are degraded with release of by-products providing an important nutrient source for the host and additional health benefits. Similarly, the immunological importance of the gut microbiota is well-recognized and 20 is exemplified in germfree animals which have an impaired immune system that is functionally reconstituted following the introduction of commensal bacteria [iv-vi].

[0003] Dramatic changes in microbiota composition have been documented in gastrointestinal disorders such as inflammatory bowel disease (IBD). For example, the levels of *Clostridium* cluster XIVa and *Clostridium* cluster XI (*F. prausnitzii*) bacteria are reduced in IBD patients whilst numbers of *E. coli* are increased, suggesting a shift in the balance 25 of symbionts and pathobionts within the gut [vii-xi].

[0004] In recognition of the potential positive effect that certain bacterial strains may have on the animal gut, various strains have been proposed for use in the treatment of various diseases (see, for example, [xii-xv]). A number of strains, including mostly *Lactobacillus* and *Bifidobacterium* strains, have been proposed for use in treating various bowel disorders (see [xvi] for a review). Strains of the genus *Blautia* have also been proposed for use in modulating the microbial balance 30 of the digestive ecosystem in IBS patients (WO 01/85187). However, the relationship between different bacterial strains and different diseases, and the precise effects of particular bacterial strains on the gut and at a systemic level and on any particular types of diseases, are poorly characterised.

[0005] There is a requirement for the potential effects of gut bacteria to be characterised so that new therapies using gut bacteria can be developed.

35 [0006] US 2010/0247489 describes the use of mineral nutrients to treat digestive disorders. US'789 proposes optionally also using numerous different genera of bacteria, including *Enterobacteriaceae*, to prevent and reduce gas formation in the colon, so this document suggests that increasing *Enterobacteriaceae* spp. in the gastrointestinal tract may be employed to treat certain diseases. US'789 does not discuss any methods for reducing *Enterobacteriaceae* spp.

[0007] WO 2016/086206 suggests that bacteria in the order Clostridiales, including *Enterbacteriaceace* spp., can be 40 used to treat or prevent dysbiosis. There is no suggestion in WO'206 that reducing the level of *Enterobacteriaceace* spp. in the gastrointestinal tract can be used to treat diseases, nor any suggestion regarding how a reduction in the level of *Enterbacteriaceace* spp. might be achieved.

[0008] WO 2012/142605 proposes that it may be possible to treat a number of different diseases with a combination 45 of microorganisms. WO'605 suggests a large number of possible bacterial species that could be employed, but there is no teaching in WO'605 as to how any of the proposed bacterial species could be used to treat any of the diseases proposed.

**SUMMARY OF THE INVENTION**

50 [0009] The inventors have developed new therapies for treating and preventing diseases associated with *Enterobacteriaceae*, in particular *E. coli*. In particular, the inventors have identified that bacterial strains from the genus *Blautia* can be effective for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract. As described in the examples, oral administration of compositions comprising *Blautia hydrogenotrophica* may reduce the level of *Enterobacteriaceae* in the gastrointestinal tract, including *E. coli*, and may treat or prevent diseases associated with *Enterobacteriaceae* or *E. coli*. Therefore, in a first embodiment, the invention provides a composition comprising a bacterial strain of the genus 55 *Blautia hydrogenotrophica* having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, for use in a method of reducing the level of pathogenoc *Enterobacteriaceae* in the gastrointestinal tract.

[0010] In preferred embodiments of all aspects of the invention, the *Enterobacteriaceae* is *E. coli*. The bacterial strain is of *Blautia hydrogenotrophica* as defined in the claims and is preferably the bacterium deposited under accession

number DSM 10507/14294.

[0011] In preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus *Blautia*, for use in a method of treating or preventing a disease associated with *Enterobacteriaceae* infection, such as *E. coli* infection, as defined in the claims. In certain embodiments, the compositions of the invention are for use in treating or preventing diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis. In certain embodiments, the compositions of the invention are for use in treating or preventing *Enterobacteriaceae* infection, such as *E. coli* infection.

[0012] In further preferred embodiments, the compositions of the invention, as defined in the claims, are for use in reducing the level of *Enterobacteriaceae* in the gastrointestinal tract, preferably the level of *E. coli*, in the treatment or prevention of IBS, Crohn's disease, ulcerative colitis, functional dyspepsia, diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis.

[0013] The inventors have developed new therapies for treating and preventing diarrhoea. In particular, the inventors have identified that bacterial strains from the genus *Blautia* can be effective for reducing diarrhoea. As described in the examples, oral administration of compositions comprising *Blautia hydrogenotrophica* may reduce diarrhoea in patients having irritable bowel syndrome (IBS).

[0014] The bacterial strain in the composition is of *Blautia hydrogenotrophica*. Closely related strains may also be used, such as bacterial strains that have a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Blautia hydrogenotrophica*. Preferably, the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5. Most preferably, the bacterial strain in the composition is the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294.

[0015] In certain embodiments, the composition of the invention is for oral administration. Oral administration of the strains of the invention can be effective for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract. Also, oral administration is convenient for patients and practitioners and allows delivery to and / or partial or total colonisation of the intestine.

[0016] In certain embodiments, the composition of the invention comprises one or more pharmaceutically acceptable excipients or carriers.

[0017] In certain embodiments, the composition of the invention comprises a bacterial strain that has been lyophilised. Lyophilisation is an effective and convenient technique for preparing stable compositions that allow delivery of bacteria, and is shown to provide effective compositions in the examples.

[0018] In certain embodiments, the invention provides a food product comprising the composition as described above.

[0019] The disclosure provides a vaccine composition comprising the composition as described above.

[0020] Additionally, the invention provides a method of reducing the level of *Enterobacteriaceae* in the gastrointestinal tract and thereby treating or preventing diseases associated with *Enterobacteriaceae*, comprising administering a composition comprising a bacterial strain of the genus *Blautia*, as defined in the claims.

## BRIEF DESCRIPTION OF DRAWINGS

[0021]

**Figure 1:** Measurement of BH population by qPCR, showing an increase in BH at days 14 and 28 for IBS HMI rats receiving the BH lyophilisate.

**Figure 2:** Dosing study in HIM rats - RT-PCR quantification of *B. hydrogenotrophica* in fecal samples of Healthy HIM rats receiving different concentration of the bacterial species.

**Figure 3:** Transit time of *B. hydrogenotrophica* after oral administration (10<sup>9</sup>/day) to healthy HIM rats.

**Figure 4:** Comparison of *B. hydrogenotrophica* levels found in fecal and caecal samples of healthy HIM rats (RT-PCR quantification) after 14 days administration - *B. hydrogenotrophica* administrated at 10<sup>10</sup> /day/rat.

**Figure 5:** Effect of *B. hydrogenotrophica* administration on faecal microbiota composition of healthy-human microbiota-associated rats. Administration of 10<sup>10</sup> *B. hydrogenotrophica* / day for 14 days (results from 2 healthy human faecal microbiota (20 HIM rats)- qPCR analysis).

**Figure 6:** Impact of *B. hydrogenotrophica* administration on the microbial populations in IBS-HIM rats.

**Figure 7a:** Change in levels of patient microbiota *Blautia hydrogenotrophica* during and following Blautix treatment.

**Figure 7b:** Change in levels of patient microbiota *Enterobacteria* during and following Blautix treatment.

**Figure 8:** Hydrogen breath test Cmax results for day 1, day 2, day 15 and day 16 for IBS patients treated with Blautix (Figure 8a) and IBS patients treated with placebo (Figure 8b). **Figure 8c** is a graph comparing the percentage of Blautix treated patients with a reduction in hydrogen between the mean of days 15 and 16 and the mean of days 1 and 2 to the percentage of placebo treated patients with a reduction in hydrogen between these time points.

**Figure 9a:** Hydrogen uncorrected and hydrogen corrected breath test paired data for day 1 and day 15 for Blautix treated IBS patients; **Figure 9b:** graph comparing mean hydrogen uncorrected breath test results for day 1 and day 15 for the Blautix treatment group; **Figure 9c:** graph comparing mean hydrogen corrected breath test results for day 1 and day 15 for the Blautix treatment group.

**Figure 10a:** Hydrogen uncorrected and hydrogen corrected breath test paired data for day 1 and day 15 for placebo treated IBS patients; **Figure 10b:** graph comparing mean hydrogen uncorrected breath test results for day 1 and day 15 for the placebo group; **Figure 10c:** graph comparing mean hydrogen corrected breath test results for day 1 and day 15 for the placebo group.

**Figure 11:** Graphs comparing the mean hydrogen breath test results from day 1 and day 15 for the Bautix treatment group (Verum) and placebo group (Figure 11a: uncorrected hydrogen; Figure 11b: corrected hydrogen).

**Figure 12:** qPCR evaluation of *B. hydrogenotrophica* population in faecal samples of IBS-HMA rats treated or not with a composition comprising *B. hydrogenotrophica* (BlautiX) for 28 days.

**Figure 13:** Bacteria enumeration in IBS HMA-rat faecal samples after *B. hydrogenotrophica* (BlautiX) administration versus control solution..

**Figure 14:** Changes in patient symptoms during dosing period (days 1-16) of Phase I clinical trial.

**Figure 15:** Changes in patient symptoms during washout period of Phase I clinical trial.

## DISCLOSURE OF THE INVENTION

### Bacterial strains

**[0022]** The compositions of the invention comprise a bacterial strain of the genus *Blautia hydrogenotrophica* having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5. The examples demonstrate that bacteria of this species are useful for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract, in particular *E. coli*. The bacterial strains are of the species *Blautia hydrogenotrophica*. Most preferred is the bacterium deposited under accession number DSM 10507/14294.

**[0023]** The *Blautia* species are Gram-reaction-positive, non-motile bacteria that may be either coccoid or oval and all are obligate anaerobes that produce acetic acid as the major end product of glucose fermentation [xvii]. *Blautia* may be isolated from the human gut, although *B. producta* was isolated from a septicaemia sample.

**[0024]** *Blautia hydrogenotrophica* (previously known as *Ruminococcus hydrogenotrophicus*) has been isolated from the guts of mammals, is strictly anaerobic, and metabolises H<sub>2</sub>/CO<sub>2</sub> to acetate, which may be important for human nutrition and health. The type strain of *Blautia hydrogenotrophica* is S5a33 = DSM 10507 = JCM 14656. The GenBank accession number for the 16S rRNA gene sequence of *Blautia hydrogenotrophica* strain S5a36 is X95624.1 (disclosed herein as SEQ ID NO:5). This exemplary *Blautia hydrogenotrophica* strain is described in [xvii] and [xviii]. The S5a33 strain and the S5a36 strain correspond to two subclones of a strain isolated from a faecal sample of a healthy subject. They show identical morphology, physiology and metabolism and have identical 16S rRNA sequences. Thus, in some embodiments, the *Blautia hydrogenotrophica* for use in the invention has the 16S rRNA sequence of SEQ ID NO:5.

**[0025]** The *Blautia hydrogenotrophica* bacterium deposited under accession number DSM 10507 and also under accession number DSM 14294 was tested in the examples and is also referred to herein as strain BH. Strain BH was deposited with the Deutsche Sammlung von Mikroorganismen [German Microorganism Collection] (Mascheroder Weg 1b, 38124 Braunschweig, Germany) in 26th January 1996 as "*Ruminococcus hydrogenotrophicus*" under accession number DSM 10507 and also under accession number DSM 14294 as "S5a33" on 14th May 2001. The depositor was INRA Laboratoire de Microbiologie CR de Clermont-Ferrand/Theix 63122 Saint Genes Champanelle, France. Ownership of the deposits has passed to 4D Pharma Plc by way of assignment.

**[0026]** Bacterial strains closely related to the strain tested in the examples are also expected to be effective for reducing

the level of *Enterobacteriaceae* in the gastrointestinal tract, in particular *E. coli*. In certain embodiments, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Blautia hydrogenotrophica*. Preferably, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5.

[0027] Bacterial strains that are biotypes of the bacterium deposited under accession number DSM 10507/14294 are also expected to be effective for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract, in particular *E. coli*. A biotype is a closely related strain that has the same or very similar physiological and biochemical characteristics.

[0028] Strains that are biotypes of a bacterium deposited under accession number DSM 10507/14294 and that are suitable for use in the invention may be identified by sequencing other nucleotide sequences for a bacterium deposited under accession number DSM 10507/14294. For example, substantially the whole genome may be sequenced and a biotype strain for use in the invention may have at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity across at least 80% of its whole genome (e.g. across at least 85%, 90%, 95% or 99%, or across its whole genome). For example, in some embodiments, a biotype strain has at least 98% sequence identity across at least 98% of its genome or at least 99% sequence identity across 99% of its genome. Other suitable sequences for use in identifying biotype strains may include hsp60 or repetitive sequences such as BOX, ERIC, (GTG)<sub>5</sub>, or REP or [xx]. Biotype strains may have sequences with at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to the corresponding sequence of a bacterium deposited under accession number DSM 10507/14294. In some embodiments, a biotype strain has a sequence with at least 97%, 98%, 99%, 99.5% or 99.9% sequence identity to the corresponding sequence of the *Blautia hydrogenotrophica* strain deposited as DSM 10507/14294 and comprises a 16S rRNA sequence that is at least 99% identical (e.g. at least 99.5% or at least 99.9% identical) to SEQ ID NO:5. In some embodiments, a biotype strain has a sequence with at least 97%, 98%, 99%, 99.5% or 99.9% sequence identity to the corresponding sequence of the *Blautia hydrogenotrophica* strain deposited as DSM 10507/14294 and has the 16S rRNA sequence of SEQ ID NO:5.

[0029] Alternatively, strains that are biotypes of a bacterium deposited under accession number DSM 10507/14294 and that are suitable for use in the invention may be identified by using the accession number DSM 10507/14294 deposit and restriction fragment analysis and/or PCR analysis, for example by using fluorescent amplified fragment length polymorphism (FAFLP) and repetitive DNA element (rep)-PCR fingerprinting, or protein profiling, or partial 16S or 23s rDNA sequencing. In preferred embodiments, such techniques may be used to identify other *Blautia hydrogenotrophica* strains.

[0030] In certain embodiments, strains that are biotypes of a bacterium deposited under accession number DSM 10507/14294 and that are suitable for use in the invention are strains that provide the same pattern as a bacterium deposited under accession number DSM 10507/14294 when analysed by amplified ribosomal DNA restriction analysis (ARDRA), for example when using Sau3AI restriction enzyme (for exemplary methods and guidance see, for example, [xx]). Alternatively, biotype strains are identified as strains that have the same carbohydrate fermentation patterns as a bacterium deposited under accession number DSM 10507/14294.

[0031] Other *Blautia* strains that are useful in the compositions and methods of the invention, such as biotypes of a bacterium deposited under accession number DSM 10507/14294, may be identified using any appropriate method or strategy, including the assays described in the examples. For instance, strains for use in the invention may be identified by culturing bacteria and administering to rats to test in the distension assay. In particular, bacterial strains that have similar growth patterns, metabolic type and/or surface antigens to a bacterium deposited under accession number DSM 10507/14294 may be useful in the invention. A useful strain will have comparable microbiota modulatory activity to the DSM 10507/14294 strain. In particular, a biotype strain will elicit comparable effects on *Enterobacteriaceae* to the effects shown in the Examples, which may be identified by using the culturing and administration protocols described in the Examples.

[0032] A particularly preferred strain of the invention is the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294. This is the exemplary BH strain tested in the examples and shown to be effective for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract, in particular *E. coli*. Therefore, the invention provides a cell, such as an isolated cell, of the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294, or a derivative thereof, for use in therapy, in particular for the diseases described herein.

[0033] A derivative of the strain deposited under accession number DSM 10507/14294 may be a daughter strain (progeny) or a strain cultured (subcloned) from the original. A derivative of a strain of the invention may be modified, for example at the genetic level, without ablating the biological activity. In particular, a derivative strain of the invention is therapeutically active. A derivative strain will have comparable microbiota modulatory activity to the original DSM 10507/14294 strain. In particular, a derivative strain will elicit comparable effects on *Enterobacteriaceae* to the effects shown in the Examples, which may be identified by using the culturing and administration protocols described in the Examples. A derivative of the DSM 10507/14294 strain will generally be a biotype of the DSM 10507/14294 strain.

[0034] References to cells of the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294 encompass any cells that have the same safety and therapeutic efficacy characteristics as the strains

deposited under accession number DSM 10507/14294, and such cells are encompassed by the invention.

[0035] In preferred embodiments, the bacterial strains in the compositions of the invention are viable and capable of partially or totally colonising the intestine.

5 **Therapeutic uses**

[0036] In certain embodiments, the compositions of the invention are for use in reducing the level of *Enterobacteriaceae* in the gastrointestinal tract. Increased levels of *Enterobacteriaceae* in the gastrointestinal tract are associated with numerous pathological conditions and diseases, and the examples demonstrate that the compositions of the invention may be effective for reducing the level of *Enterobacteriaceae* in the gastrointestinal tract.

[0037] In preferred embodiments of all aspects of the invention, the *Enterobacteriaceae* is *E. coli*. Therefore, preferably the compositions of the invention are for use in reducing the level of *E. coli* in the gastrointestinal tract.

[0038] In certain embodiments, the *Enterobacteriaceae* is a pathogenic strain, such as *E. coli* O157:H7, O104:H4, O121, O26, O103, O111, O145, O104:H21, or O104:H4.

15 [0039] In alternative embodiments, the *Enterobacteriaceae* is a commensal or non-pathogenic strain. Increased levels of such *Enterobacteriaceae* may contribute to conditions such as IBS and Crohn's disease, and the examples demonstrate that the compositions of the invention may have a reducing effect on *Enterobacteriaceae* in the context of IBS.

20 [0040] In certain embodiments, the compositions of the invention are for use in treating or preventing a disease associated with *Enterobacteriaceae* infection, such as *E. coli* infection. In certain embodiments, the compositions of the invention are for use in treating or preventing diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis. In such embodiments the *Enterobacteriaceae* may be a pathogenic strain.

25 [0041] In certain embodiments, the compositions of the invention are for use in treating or preventing a disease associated with increased levels of *Enterobacteriaceae*, such as *E. coli*. In certain embodiments, the compositions of the invention are for use in treating or preventing diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis. In such embodiments, the *Enterobacteriaceae* may be a commensal or non-pathogenic strain.

30 [0042] In some embodiments, the pathogenesis of the disease or condition affects the intestine. In some embodiments, the pathogenesis of the disease or condition does not affect the intestine. In some embodiments, the pathogenesis of the disease or condition is not localised at the intestine. In some embodiments, the treating or preventing occurs at a site other than at the intestine. In some embodiments, the treating or preventing occurs at the intestine and also at a site other than at the intestine. In certain embodiments, the disease or condition is systemic.

35 [0043] In certain embodiments, the compositions of the invention are for use in treating or preventing *Enterobacteriaceae* infection, such as *E. coli* infection. In preferred embodiments, the compositions of the invention are for use in treating or preventing infection of the gastrointestinal tract, and in particular the caecum. In such embodiments the *Enterobacteriaceae* may be a pathogenic strain.

40 [0044] In some embodiments, the level of *Enterobacteriaceae* is reduced in stool in the subject. In some embodiments, the level of *Enterobacteriaceae* is reduced in a stool sample from the subject. In some embodiments, the level of *Enterobacteriaceae* is reduced in the distal gut of the subject. In some embodiments, the level of *Enterobacteriaceae* is reduced in the caecum. In some embodiments, the level of *Enterobacteriaceae* is reduced in the colon. In some embodiments, the level of *Enterobacteriaceae* is reduced in the rectum. In some embodiments, the level of *Enterobacteriaceae* is reduced in the small intestine.

45 [0045] In preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus *Blautia hydrogenotrophica* having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, for use in the treatment of infections caused by pathogenic *Enterobacteriaceae*.

50 [0046] In preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus *Blautia hydrogenotrophica* having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, for use in the treatment of *E. coli* infection.

55 [0047] In preferred embodiments, the compositions of the invention are for use in reducing the level of *Enterobacteriaceae* in the gastrointestinal tract, preferably the level of *E. coli*, in the treatment or prevention of a disease associated with increased levels of *Enterobacteriaceae*, such as IBS, Crohn's disease, ulcerative colitis, functional dyspepsia, diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis. *Enterobacteriaceae* and in particular *E. coli* are known to be potential triggers for, or known to exacerbate, Crohn's disease and ulcerative colitis [xxii-xxiv], so the effect shown in the examples for the compositions of the invention may be beneficial in the treatment of these conditions.

[0048] In certain embodiments, the compositions of the invention are for use in treating or preventing IBS, Crohn's disease, ulcerative colitis, functional dyspepsia, diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis by reducing the level of *Enterobacteriaceae* in the gastrointestinal tract.

[0049] In preferred embodiments, the compositions of the invention comprise the bacterium deposited under accession number DSM 10507/14294 and are for use in reducing the level of *Enterobacteriaceae* in the gastrointestinal tract in the treatment of Crohn's disease, ulcerative colitis, functional dyspepsia, or most preferably IBS. In further preferred

embodiments, the compositions of the invention comprise the bacterium deposited under accession number DSM 10507/14294 and are for use in treating or preventing Crohn's disease, ulcerative colitis, functional dyspepsia, or most preferably IBS by reducing the level of *Enterobacteriaceae* in the gastrointestinal tract.

**[0050]** In certain embodiments, the composition is administered in combination with an antibiotic, such as a fluoroquinolone, azithromycin, ciprofloxacin or rifaximin. In certain embodiments, the composition is administered in combination with a dehydration treatment such as oral rehydration solution. The composition of the invention may be administered at the same time as the antibiotic or dehydration treatment, or sequentially with the antibiotic or dehydration treatment.

**[0051]** In certain embodiments, the compositions are for use in patients that exhibit, or are expected to exhibit, increased levels of *Enterobacteriaceae* in the gastrointestinal tract, for example, when compared to a healthy subject, or a population of healthy subjects.

**[0052]** In certain embodiments, the compositions of the invention are for use in a method of treating, preventing or reducing colonisation of the gastrointestinal tract by *Enterobacteriaceae*.

**[0053]** In some embodiments, the composition of the invention is for use in a method of reducing the level of *Enterobacteriaceae* in the gastrointestinal tract in a subject having an increased level of hydrogen in their breath relative to a healthy subject. In some embodiments, the composition of the invention is for use in reducing the hydrogen level in the breath of a subject exhibiting or who is expected to exhibit an increased level of *Enterobacteriaceae* in the gastrointestinal tract. The subject is preferably a subject diagnosed as having IBS, Crohn's disease, ulcerative colitis, functional dyspepsia, diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis and/or an infection caused by pathogenic *Enterobacteriaceae*, for example, *E. coli*. The examples show that treatment with a composition of the invention reduces the level of hydrogen detected in hydrogen breath tests. Accordingly, the hydrogen levels are preferably assessed using a hydrogen breath test. The hydrogen breath test is well known in the art and so the skilled person will know how to conduct such a test. In some embodiments, the patient is administered lactulose as the substrate for the test.

**[0054]** The hydrogen breath test is also a useful tool for monitoring the effectiveness or likely effectiveness of reducing the level of *Enterobacteriaceae* and of treatment or prevention using a composition of the invention. For example, a reduction in the level of hydrogen detected in a subject's breath following treatment with a composition of the invention may indicate that the treatment is having a reducing, therapeutic or preventative effect. Accordingly, in some embodiments the methods and uses of the invention further comprise monitoring the hydrogen level in a subject's breath during and/or following treatment with a composition of the invention and thereby assessing the effectiveness or likely effectiveness of reducing, treatment or prevention. For example, hydrogen levels may be monitored at one or more (e.g. 1, 2, 3, 4 or more than 4) times, for example, including before treatment, at the start of treatment, during treatment, at the end of treatment and/or following treatment, as desired. In some embodiments, the level of hydrogen in the subject's breath at the end and/or following the dosing period (during which the composition is administered to the subject) is compared to the level at the start and/or before the dosing period and a reduction in the level indicates the effectiveness or likely effectiveness of the reducing, treatment or prevention. For example, in embodiments in which the dosing period is 16 days, it may be desirable to take measurements at day 1 and day 16, or for example at day 1, day 2, day 15 and day 16. In some embodiments, multiple measurements are taken and the mean of those measurements obtained (for example, the mean of day 1 and day 2 and the mean of day 15 and day 16). In some embodiments, a reduction in at least 40 ppm in the hydrogen level Cmax indicates that the reducing, treatment or prevention is effective or likely to be effective. In some embodiments, the hydrogen level in the subject's breath is measured only once, for example, at the end of or following treatment, and the finding that the level is at or close to a predetermined level is indicative that the reducing, treatment or prevention is likely to have been effective. The hydrogen breath test is a standard assay and so predetermined levels are known in the art.

**[0055]** Treatment or prevention may refer to, for example, an alleviation of the severity of symptoms or a reduction in the frequency of exacerbations or the range of triggers that are a problem for the patient.

**[0056]** Levels of *Enterobacteriaceae* may be detected in faeces from a patient, using standard techniques, such as the qPCR techniques used in the examples.

#### **Modes of administration**

**[0057]** Preferably, the compositions of the invention are to be administered to the gastrointestinal tract in order to enable delivery to and / or partial or total colonisation of the intestine with the bacterial strain of the invention. Generally, the compositions of the invention are administered orally, but they may be administered rectally, intranasally, or via buccal or sublingual routes.

**[0058]** In certain embodiments, the compositions of the invention may be administered as a foam, as a spray or a gel.

**[0059]** In certain embodiments, the compositions of the invention may be administered as a suppository, such as a rectal suppository, for example in the form of a theobroma oil (cocoa butter), synthetic hard fat (e.g. suppocire, witepsol), glycero-gelatin, polyethylene glycol, or soap glycerin composition.

**[0060]** In certain embodiments, the composition of the invention is administered to the gastrointestinal tract via a tube,

such as a nasogastric tube, orogastric tube, gastric tube, jejunostomy tube (J tube), percutaneous endoscopic gastrostomy (PEG), or a port, such as a chest wall port that provides access to the stomach, jejunum and other suitable access ports.

**[0061]** The compositions of the invention may be administered once, or they may be administered sequentially as part of a treatment regimen. In certain embodiments, the compositions of the invention are to be administered daily. The examples demonstrate that daily administration provides successfully colonisation and clinical benefits.

**[0062]** In certain embodiments, the compositions of the invention are administered regularly, such as daily, every two days, or weekly, for an extended period of time, such as for at least one week, two weeks, one month, two months, six months, or one year. The examples demonstrate that BH administration may not result in permanent colonisation of the intestines, so regular administration for extended periods of time may provide greater therapeutic benefits.

**[0063]** In some embodiments the compositions of the invention are administered for 7 days, 14 days, 16 days, 21 days or 28 days or no more than 7 days, 14 days, 16 days, 21 days or 28 days. For example, in some embodiments the compositions of the invention are administered for 16 days.

**[0064]** In certain embodiments of the invention, treatment according to the invention is accompanied by assessment of the patient's gut microbiota. Treatment may be repeated if delivery of and/or partial or total colonisation with the strain of the invention is not achieved such that efficacy is not observed, or treatment may be ceased if delivery and / or partial or total colonisation is successful and efficacy is observed.

**[0065]** In certain embodiments, the composition of the invention may be administered to a pregnant animal, for example a mammal such as a human in order to prevent elevated levels of *Enterobacteriaceae* developing in her child *in utero* and / or after it is born.

**[0066]** The compositions of the invention may be administered to a patient that has been diagnosed with elevated levels of *Enterobacteriaceae* or a disease or condition associated with elevated levels of *Enterobacteriaceae*, or that has been identified as being at risk of elevated levels of *Enterobacteriaceae*. The compositions may also be administered as a prophylactic measure to prevent the development of elevated levels of *Enterobacteriaceae* in a healthy patient.

**[0067]** The compositions of the invention may be administered to a patient that has been identified as having an abnormal gut microbiota. For example, the patient may have reduced or absent colonisation by *Blautia*, and in particular *Blautia hydrogenotrophica*, *Blautia stercoris* or *Blautia wexlerae*.

**[0068]** The compositions of the invention may be administered as a food product, such as a nutritional supplement.

**[0069]** Generally, the compositions of the invention are for the treatment of humans, although they may be used to treat animals including monogastric mammals such as poultry, pigs, cats, dogs, horses or rabbits. The compositions of the invention may be useful for enhancing the growth and performance of animals. If administered to animals, oral gavage may be used.

**[0070]** In some embodiments, the subject to whom the composition is to be administered is an adult human. In some embodiments, the subject to whom the composition is to be administered is an infant human.

### **Compositions**

**[0071]** Generally, the composition of the invention comprises bacteria as defined in the claims. In preferred embodiments of the invention, the composition is formulated in freeze-dried form. For example, the composition of the invention may comprise granules or gelatin capsules, for example hard gelatin capsules, comprising a bacterial strain of the invention.

**[0072]** Preferably, the composition of the invention comprises lyophilised bacteria. Lyophilisation of bacteria is a well-established procedure and relevant guidance is available in, for example, references [xxv-xxvii]. The examples demonstrate that lyophilisate compositions are particularly effective.

**[0073]** Alternatively, the composition of the invention may comprise a live, active bacterial culture. The examples demonstrate that cultures of the bacteria of the invention are therapeutically effective.

**[0074]** In some embodiments, the bacterial strain in the composition of the invention has not been inactivated, for example, has not been heat-inactivated. In some embodiments, the bacterial strain in the composition of the invention has not been killed, for example, has not been heat-killed. In some embodiments, the bacterial strain in the composition of the invention has not been attenuated, for example, has not been heat-attenuated. For example, in some embodiments, the bacterial strain in the composition of the invention has not been killed, inactivated and/or attenuated. For example, in some embodiments, the bacterial strain in the composition of the invention is live. For example, in some embodiments, the bacterial strain in the composition of the invention is viable. For example, in some embodiments, the bacterial strain in the composition of the invention is capable of partially or totally colonising the intestine. For example, in some embodiments, the bacterial strain in the composition of the invention is viable and capable of partially or totally colonising the intestine.

**[0075]** In some embodiments, the composition comprises a mixture of live bacterial strains and bacterial strains that have been killed.

[0076] In preferred embodiments, the composition of the invention is encapsulated to enable delivery of the bacterial strain to the intestine. Encapsulation protects the composition from degradation until delivery at the target location through, for example, rupturing with chemical or physical stimuli such as pressure, enzymatic activity, or physical disintegration, which may be triggered by changes in pH. Any appropriate encapsulation method may be used. Exemplary encapsulation techniques include entrapment within a porous matrix, attachment or adsorption on solid carrier surfaces, self-aggregation by flocculation or with cross-linking agents, and mechanical containment behind a microporous membrane or a microcapsule. Guidance on encapsulation that may be useful for preparing compositions of the invention is available in, for example, references [xxviii-xxix].

[0077] The composition may be administered orally and may be in the form of a tablet, capsule or powder. Encapsulated products are preferred because *Blautia* are anaerobes. Other ingredients (such as vitamin C, for example), may be included as oxygen scavengers and prebiotic substrates to improve the delivery and / or partial or total colonisation and survival *in vivo*. Alternatively, the probiotic composition of the invention may be administered orally as a food or nutritional product, such as milk or whey based fermented dairy product, or as a pharmaceutical product.

[0078] The composition may be formulated as a probiotic.

[0079] A composition of the invention includes a therapeutically effective amount of a bacterial strain of the invention. A therapeutically effective amount of a bacterial strain is sufficient to exert a beneficial effect upon a patient. A therapeutically effective amount of a bacterial strain may be sufficient to result in delivery to and/or partial or total colonisation of the patient's intestine.

[0080] A suitable daily dose of the bacteria, for example for an adult human, may be from about  $1 \times 10^3$  to about  $1 \times 10^{11}$  colony forming units (CFU); for example, from about  $1 \times 10^7$  to about  $1 \times 10^{10}$  CFU; in another example from about  $1 \times 10^6$  to about  $1 \times 10^{10}$  CFU; in another example from about  $1 \times 10^7$  to about  $1 \times 10^{11}$  CFU; in another example from about  $1 \times 10^8$  to about  $1 \times 10^{10}$  CFU; in another example from about  $1 \times 10^8$  to about  $1 \times 10^{11}$  CFU.

[0081] In certain embodiments, the dose of the bacteria is at least  $10^9$  cells per day, such as at least  $10^{10}$ , at least  $10^{11}$ , or at least  $10^{12}$  cells per day.

[0082] In certain embodiments, the composition contains the bacterial strain in an amount of from about  $1 \times 10^6$  to about  $1 \times 10^{11}$  CFU/g, respect to the weight of the composition; for example, from about  $1 \times 10^8$  to about  $1 \times 10^{10}$  CFU/g. The dose may be, for example, 1 g, 3g, 5g, and 10g.

[0083] Typically, a probiotic, such as the composition of the invention, is optionally combined with at least one suitable prebiotic compound. A prebiotic compound is usually a non-digestible carbohydrate such as an oligo- or polysaccharide, or a sugar alcohol, which is not degraded or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and transgalacto-oligosaccharides.

[0084] In certain embodiments, the probiotic composition of the present invention includes a prebiotic compound in an amount of from about 1 to about 30% by weight, respect to the total weight composition, (e.g. from 5 to 20% by weight). Carbohydrates may be selected from the group consisting of: fructo- oligosaccharides (or FOS), short-chain fructo-oligosaccharides, inulin, isomalt-oligosaccharides, pectins, xylo-oligosaccharides (or XOS), chitosan-oligosaccharides (or COS), beta-glucans, arable gum modified and resistant starches, polydextrose, D-tagatose, acacia fibers, carob, oats, and citrus fibers. In one aspect, the prebiotics are the short-chain fructo-oligosaccharides (for simplicity shown herein below as FOSs-c.c); said FOSs-c.c. are not digestible carbohydrates, generally obtained by the conversion of the beet sugar and including a saccharose molecule to which three glucose molecules are bonded.

[0085] The compositions of the invention may comprise pharmaceutically acceptable excipients or carriers. Examples of such suitable excipients may be found in the reference [xxx]. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in reference [xxxi]. Examples of suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like. Examples of suitable diluents include ethanol, glycerol and water. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as, or in addition to, the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s). Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Preservatives, stabilizers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid, cysteine and esters of p-hydroxybenzoic acid, for example, in some embodiments the preservative is selected from sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used. A further example of a suitable carrier is saccharose. A further example of a preservative is cysteine.

[0086] The compositions of the invention may be formulated as a food product. For example, a food product may provide nutritional benefit in addition to the therapeutic effect of the invention, such as in a nutritional supplement. Similarly, a food product may be formulated to enhance the taste of the composition of the invention or to make the

composition more attractive to consume by being more similar to a common food item, rather than to a pharmaceutical composition. In certain embodiments, the composition of the invention is formulated as a milk-based product. The term "milk-based product" means any liquid or semi-solid milk- or whey- based product having a varying fat content. The milk-based product can be, e.g., cow's milk, goat's milk, sheep's milk, skimmed milk, whole milk, milk recombined from powdered milk and whey without any processing, or a processed product, such as yoghurt, curdled milk, curd, sour milk, sour whole milk, butter milk and other sour milk products. Another important group includes milk beverages, such as whey beverages, fermented milks, condensed milks, infant or baby milks; flavoured milks, ice cream; milk-containing food such as sweets.

**[0087]** In some embodiments, the compositions of the invention, as defined in the claims, comprise one or more bacterial strains of the genus *Blautia* and do not contain bacteria from any other genus, or which comprise only *de minimis* or biologically irrelevant amounts of bacteria from another genus.

**[0088]** In certain embodiments, the compositions of the invention, as defined in the claims, contain a single bacterial strain or species and do not contain any other bacterial strains or species. Such compositions may comprise only *de minimis* or biologically irrelevant amounts of other bacterial strains or species. Such compositions may be a culture that is substantially free from other species of organism. In some embodiments, such compositions may be a lyophilisate that is substantially free from other species of organism.

**[0089]** In certain embodiments, the compositions of the invention, as defined in the claims, comprise one or more bacterial strains of the genus *Blautia*, for example, a *Blautia hydrogenotrophica*, and do not contain any other bacterial genus, or which comprise only *de minimis* or biologically irrelevant amounts of bacteria from another genus. In certain embodiments, the compositions of the invention comprise *Blautia hydrogenotrophica*, and do not contain any other bacterial species, or comprise only *de minimis* or biologically irrelevant amounts of bacteria from another species. In certain embodiments, the compositions of the invention comprise a single strain of *Blautia hydrogenotrophica*, and do not contain any other bacterial strains or species, or comprise only *de minimis* or biologically irrelevant amounts of bacteria from another strain or species.

**[0090]** In some embodiments, the compositions of the invention comprise more than one bacterial strain or species. For example, in some embodiments, the compositions of the invention comprise more than one strain from within the same species (e.g. more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or 45 strains), and, optionally, do not contain bacteria from any other species. In some embodiments, the compositions of the invention comprise less than 50 strains from within the same species (e.g. less than 45, 40, 35, 30, 25, 20, 15, 12, 10, 9, 8, 7, 6, 5, 4 or 3 strains), and, optionally, do not contain bacteria from any other species. In some embodiments, the compositions of the invention comprise 1-40, 1-30, 1-20, 1-19, 1-18, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6-30, 6-15, 16-25, or 31-50 strains from within the same species and, optionally, do not contain bacteria from any other species. In some embodiments, the compositions of the invention comprise more than one species from within the same genus (e.g. more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 23, 25, 30, 35 or 40 species), and, optionally, do not contain bacteria from any other genus. In some embodiments, the compositions of the invention comprise less than 50 species from within the same genus (e.g. less than 50, 45, 40, 35, 30, 25, 20, 15, 12, 10, 8, 7, 6, 5, 4 or 3 species), and, optionally, do not contain bacteria from any other genus. In some embodiments, the compositions of the invention comprise 1-50, 1-40, 1-30, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6-30, 6-15, 16-25, or 31-50 species from within the same genus and, optionally, do not contain bacteria from any other genus. The invention comprises any combination of the foregoing.

**[0091]** In some embodiments, the composition comprises a microbial consortium. For example, in some embodiments, the composition comprises the *Blautia hydrogenotrophica* bacterial strain as defined in the claims as part of a microbial consortium. For example, in some embodiments, the *Blautia hydrogenotrophica* bacterial strain is present in combination with one or more (e.g. at least 2, 3, 4, 5, 10, 15 or 20) other bacterial strains from other genera with which it can live symbiotically *in vivo* in the intestine. For example, in some embodiments, the composition comprises a bacterial strain of *Blautia hydrogenotrophica* in combination with a bacterial strain from a different genus. In some embodiments, the microbial consortium comprises two or more bacterial strains obtained from a faeces sample of a single organism, e.g. a human. In some embodiments, the microbial consortium is not found together in nature. For example, in some embodiments, the microbial consortium comprises bacterial strains obtained from faeces samples of at least two different organisms. In some embodiments, the two different organisms are from the same species, e.g. two different humans. In some embodiments, the two different organisms are an infant human and an adult human. In some embodiments, the two different organisms are a human and a non-human mammal.

**[0092]** In some embodiments, the composition of the invention additionally comprises a bacterial strain that has the same safety and therapeutic efficacy characteristics as the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294, but which is not the *Blautia hydrogenotrophica* strain deposited under accession number DSM 10507/14294, or which is not a *Blautia hydrogenotrophica* or which is not a *Blautia*.

**[0093]** In some embodiments in which the composition of the invention comprises more than one bacterial strain, species or genus, the individual bacterial strains, species or genera may be for separate, simultaneous or sequential

administration. For example, the composition may comprise all of the more than one bacterial strain, species or genera, or the bacterial strains, species or genera may be stored separately and be administered separately, simultaneously or sequentially. In some embodiments, the more than one bacterial strains, species or genera are stored separately but are mixed together prior to use.

5 [0094] In some embodiments, the bacterial strain for use in the invention is obtained from human adult faeces. In some embodiments in which the composition of the invention comprises more than one bacterial strain, all of the bacterial strains are obtained from human adult faeces or if other bacterial strains are present they are present only in *de minimis* amounts. The bacteria may have been cultured subsequent to being obtained from the human adult faeces and being used in a composition of the invention.

10 [0095] In some embodiments, the one or more *Blautia* bacterial strains is/are the only therapeutically active agent(s) in a composition of the invention. In some embodiments, the bacterial strain(s) in the composition is/are the only therapeutically active agent(s) in a composition of the invention.

[0096] The compositions for use in accordance with the invention may or may not require marketing approval.

15 [0097] In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is lyophilised. In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is spray dried. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is live. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is viable. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is capable of partially or totally colonising the intestine. In certain embodiments, the invention provides the above pharmaceutical composition, wherein the bacterial strain is lyophilised or spray dried and wherein it is viable and capable of partially or totally colonising the intestine.

20 [0098] In some cases, the lyophilised or spray dried bacterial strain is reconstituted prior to administration. In some cases, the reconstitution is by use of a diluent described herein.

25 [0099] The compositions of the invention can comprise pharmaceutically acceptable excipients, diluents or carriers.

[0100] In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain as defined in the claims; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to reduce levels of *Enterobacteriaceae* and/or treat a disorder associated with elevated levels of *Enterobacteriaceae* when administered to a subject in need thereof; and wherein the disorder is associated with elevated levels of *Enterobacteriaceae*, such as Crohn's disease, ulcerative colitis, functional dyspepsia or, more preferably, IBS, or diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis .

30 [0101] In certain embodiments, the invention provides the above pharmaceutical composition, wherein the amount of the bacterial strain is from about  $1 \times 10^3$  to about  $1 \times 10^{11}$  colony forming units per gram with respect to a weight of the composition.

35 [0102] In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered at a dose of 1 g, 3 g, 5 g or 10 g.

[0103] In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered by a method selected from the group consisting of oral, rectal, subcutaneous, nasal, buccal, and sub-lingual.

40 [0104] In certain embodiments, the invention provides the above pharmaceutical composition, comprising a carrier selected from the group consisting of lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol and sorbitol.

[0105] In certain embodiments, the invention provides the above pharmaceutical composition, comprising a diluent selected from the group consisting of ethanol, glycerol and water.

45 [0106] In certain embodiments, the invention provides the above pharmaceutical composition, comprising an excipient selected from the group consisting of starch, gelatin, glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweetener, acacia, tragacanth, sodium alginate, carboxymethyl cellulose, polyethylene glycol, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate and sodium chloride.

50 [0107] In certain embodiments, the invention provides the above pharmaceutical composition, further comprising at least one of a preservative, an antioxidant and a stabilizer.

[0108] In certain embodiments, the invention provides the above pharmaceutical composition, comprising a preservative selected from the group consisting of sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.

55 [0109] In certain embodiments, there is provided the pharmaceutical composition of the invention, wherein the composition does not comprise any minerals, or more specifically, does not comprise any metals with an atomic number greater than 33, for example, wherein the composition does not comprise any minerals from the group consisting of selenium, molybdenum, tungsten, selenium compounds, molybdenum compounds and tungsten compounds.

[0110] In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is lyophilised.

[0111] In certain embodiments, the invention provides the above pharmaceutical composition, wherein when the composition is stored in a sealed container at about 4°C or about 25°C and the container is placed in an atmosphere having 50% relative humidity, at least 80% of the bacterial strain as measured in colony forming units, remains after a period of at least about: 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years.

5 [0112] In some embodiments, the composition of the invention is provided in a sealed container comprising a composition as described herein. In some embodiments, the sealed container is a sachet or bottle. In some embodiments, the composition of the invention is provided in a syringe comprising a composition as described herein.

10 [0113] The composition of the present invention may, in some embodiments, be provided as a pharmaceutical formulation. For example, the composition may be provided as a tablet or capsule. In some embodiments, the capsule is a gelatine capsule ("gel-cap").

[0114] In some embodiments, the compositions of the invention are administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.

15 [0115] Pharmaceutical formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solid and liquid (including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids (e.g. aqueous solutions), emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.

20 [0116] In some embodiments the pharmaceutical formulation is an enteric formulation, i.e. a gastro-resistant formulation (for example, resistant to gastric pH) that is suitable for delivery of the composition of the invention to the intestine by oral administration. Enteric formulations may be particularly useful when the bacteria or another component of the composition is acid-sensitive, e.g. prone to degradation under gastric conditions.

25 [0117] In some embodiments, the enteric formulation comprises an enteric coating. In some embodiments, the formulation is an enteric-coated dosage form. For example, the formulation may be an enteric-coated tablet or an enteric-coated capsule, or the like. The enteric coating may be a conventional enteric coating, for example, a conventional coating for a tablet, capsule, or the like for oral delivery. The formulation may comprise a film coating, for example, a thin film layer of an enteric polymer, e.g. an acid-insoluble polymer.

30 [0118] In some embodiments, the enteric formulation is intrinsically enteric, for example, gastro-resistant without the need for an enteric coating. Thus, in some embodiments, the formulation is an enteric formulation that does not comprise an enteric coating. In some embodiments, the formulation is a capsule made from a thermogelling material. In some embodiments, the thermogelling material is a cellulosic material, such as methylcellulose, hydroxymethylcellulose or hydroxypropylmethylcellulose (HPMC). In some embodiments, the capsule comprises a shell that does not contain any film forming polymer. In some embodiments, the capsule comprises a shell and the shell comprises hydroxypropylmethylcellulose and does not comprise any film forming polymer (e.g. see [xxxii]). In some embodiments, the formulation is an intrinsically enteric capsule (for example, Vcaps® from Capsugel).

35 [0119] In some embodiments, the formulation is a soft capsule. Soft capsules are capsules which may, owing to additions of softeners, such as, for example, glycerol, sorbitol, maltitol and polyethylene glycols, present in the capsule shell, have a certain elasticity and softness. Soft capsules can be produced, for example, on the basis of gelatine or starch. Gelatine-based soft capsules are commercially available from various suppliers. Depending on the method of administration, such as, for example, orally or rectally, soft capsules can have various shapes, they can be, for example, round, oval, oblong or torpedo-shaped. Soft capsules can be produced by conventional processes, such as, for example, by the Scherer process, the Accogel process or the droplet or blowing process.

### ***Culturing methods***

45 [0120] The bacterial strains for use in the present invention can be cultured using standard microbiology techniques as detailed in, for example, references [xxxiii-xxxv].

50 [0121] The solid or liquid medium used for culture may for example be YCFA agar or YCFA medium. YCFA medium may include (per 100ml, approximate values): Casitone (1.0 g), yeast extract (0.25 g), NaHCO<sub>3</sub> (0.4 g), cysteine (0.1 g), K<sub>2</sub>HPO<sub>4</sub> (0.045 g), KH<sub>2</sub>PO<sub>4</sub> (0.045 g), NaCl (0.09 g), (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> (0.09 g), MgSO<sub>4</sub> · 7H<sub>2</sub>O (0.009 g), CaCl<sub>2</sub> (0.009 g), resazurin (0.1 mg), hemin (1 mg), biotin (1 µg), cobalamin (1 µg), *p*-aminobenzoic acid (3 µg), folic acid (5 µg), and pyridoxamine (15 µg).

### ***General***

55 [0122] The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., references [xxxvi- xlvi], etc.

[0123] The term "comprising" encompasses "including" as well as "consisting" e.g. a composition "comprising" X may

consist exclusively of X or may include something additional e.g. X + Y.

[0124] The term "about" in relation to a numerical value x is optional and means, for example,  $x \pm 10\%$ .

[0125] The word "substantially" does not exclude "completely" e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.

[0126] References to a percentage sequence identity between two nucleotide sequences means that, when aligned, that percentage of nucleotides are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of ref. [xlv]. A preferred alignment is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62. The Smith-Waterman homology search algorithm is disclosed in ref. [xlv].

[0127] Unless specifically stated, a process or method comprising numerous steps may comprise additional steps at the beginning or end of the method, or may comprise additional intervening steps. Also, steps may be combined, omitted or performed in an alternative order, if appropriate.

[0128] Various embodiments of the invention are described herein. It will be appreciated that the features specified in each embodiment may be combined with other specified features, to provide further embodiments. In particular, embodiments highlighted herein as being suitable, typical or preferred may be combined with each other (except when they are mutually exclusive).

## 20 MODES FOR CARRYING OUT THE INVENTION

### ***Example 1 - Administration of bacterial inocula to rats harbouring IBS gut microbiota***

#### Summary

[0129] Rats were inoculated with the faecal microbiota from a human IBS subject. The rats were then administered with compositions comprising bacterial strains according to the invention and colonisation by *Blautia hydrogenotrophica* was analysed.

#### Strain

[0130] *Blautia hydrogenotrophica* (BH) strain DSM 10507/14294.

#### Compositions and administration

[0131] BH lyophilisate - administered by oral gavage

Control solution administered by oral gavage

#### Rats

[0132] Inoculated with human intestinal microbiota from an IBS subject.

#### Study design

[0133] Day -14 - rats inoculated with human intestinal microbiota from an IBS subject

Days 0 to 28 - daily dose of BH lyophilisate, or control solution

Days 0, 14 and 28 - qPCR of BH population in faecal samples

#### Results

[0134] Figure 1 presents the results of a qPCR analysis of the BH population in faecal samples from rats administered control solution (IBS) or BH lyophilisate (IBS+BH). An increase in the BH population was seen at days 14 and 28 in rats receiving the BH lyophilisate, which confirms successful colonisation.

#### Conclusions

[0135] Administration of compositions comprising *Blautia hydrogenotrophica* led to successful colonisation.

**Example 2 - Administration of bacterial lyophilisate to healthy rats and effect on Enterobacteriaceae**

[0136] The effects of administration of a lyophilisate of *Blautia hydrogenotrophica* (BH) strain DSM 10507/14294 on healthy HIM rats were studied and the results are reported in Figures 2-5. Further details regarding the experiments are provided above in the descriptions of the figures. Figure 2 shows that an appropriate dose for BH in rats is  $10^9$  cells per day or greater. Figure 3 shows that in these experiments BH did not permanently colonise the rat digestive tract. Figure 4 shows that BH is primarily found in the caecum. Strikingly, Figure 5 shows that administration of BH induces a statistically-significant reduction in *Enterobacteriaceae* in rat faeces as detected by qPCR.

**Example 3 - Administration of bacterial lyophilisate in a rat model of IBS**

[0137] The effects of administration of a lyophilisate of *Blautia hydrogenotrophica* (BH) strain DSM 10507/14294 on a rat model of IBS were further investigated. Germ-free rats were inoculated with faecal samples from C-IBS (with constipation) or U-IBS (unsubtyped) patients. The results are reported in Figure 6 and further details regarding the experiments are provided above in the descriptions of the figures. Figure 6 confirms that administration of BH lyophilisate causes a statistically-significant reduction in *Enterobacteriaceae*, which is mainly *E. coli*. As expected, an increase in BH is also observed.

**Example 4 -Comparison of patient microbiota Blautia hydrogenotrophica**

[0138] A Phase I clinical trial was conducted in which *Blautia hydrogenotrophica* ("Blautix", strain deposited under accession number DSM 10507/14294) was administered to human patients having irritable bowel syndrome (IBS). Patients were administered Blautix during a dosing period (day 1-16) with the washout period being day 19-23. Blautix was found to be both safe and well tolerated. Patient microbiota *Blautia hydrogenotrophica* (Blautix) were measured at day 1, day 16 and at the end of the study (EOS) with results as follows:

Table 1:

Patient	Treatment	Blautix Day 1		Blautix Day 16		Blautix EOS	
		Mean	SD	Mean	SD	Mean	SD
Placebo	Healthy	4.30E+07	8.40E+07	4.79E+07	7.63E+07	3.59E+07	6.23E+07
Blautix	Healthy	2.92E+07	2.25E+07	6.35E+07	1.02E+08	2.58E+07	3.34E+07
Placebo	IBS	3.58E+07	3.45E+07	2.44E+07	3.13E+07	2.09E+07	2.47E+07
Blautix	IBS	3.17E+07	6.28E+07	8.53E+07	1.57E+08	3.71E+07	5.56E+07

[0139] Analysis shows trends in *Blautia hydrogenotropica* levels in patient stool samples (see Figure 7a). Participants receiving Blautix have increased levels of the bacteria in their stool samples following the dosing period (day 16). This demonstrates the successful delivery of Blautix to the gut. The levels return to normal following the washout period (End-of study; EOS). Thus Blautix does not permanently colonise the gut once dosing ceases. Both observations are consistent with the pre-clinical model.

**Example 5 - Comparison of patient microbiota Enterobacteria.**

[0140] Patient microbiota Enterobacteria were also measured during the Phase I clinical trial at day 1, day 16 and at the end of the study with results as follows:

Patient	Treatment	Enterobacteria Day 1		Enterobacteria Day 16		Enterobacteria EOS	
		Mean	SD	Mean	SD	Mean	SD
Placebo	Healthy	5.89E+08	1.00E+09	3.32E+08	6.26E+08	2.85E+08	4.28E+08
Blautix	Healthy	9.96E+08	1.06E+09	4.87E+08	6.64E+08	2.70E+08	3.76E+08
Placebo	IBS	7.85E+08	1.28E+09	3.01E+08	4.92E+08	2.45E+09	2.45E+09
Blautix	IBS	8.38E+09	1.96E+10	1.12E+09	1.45E+09	6.17E+08	9.91E+08

[0141] Analysis shows trends in Enterobacteria levels in patients stool samples (see Figure 7b). IBS patients treated with Blautix had a reduction in Enterobacteria. This is consistent with observations from the preclinical model.

**Example 6 - Hydrogen breath test results**

[0142] Breath hydrogen levels are a biomarker of Blautix activity - MoA involves metabolism of endogenous H<sub>2</sub> to produce acetate. Human subjects were administered lactulose and hydrogen (H<sub>2</sub>) levels (Cmax) were sampled at four time points: day 1, day 2, day 15 and day 16. Hydrogen uncorrected results were converted to hydrogen corrected results.

[0143] Some patients were excluded from the analysis. There were three reasons why a subject was not included in the hydrogen breath test analysis: 1) They produced a CMAX hydrogen breath test result of <20 on one of the four sampling days and were therefore deemed to have not responded to the test; 2) They were methane producers (taken as producing more methane than hydrogen in the breath test), this affects the hydrogen response; and/or 3) there was an aberrant value obtained in the hydrogen breath test (232 ppm). Subjects 3.12 (Blautix), 3.24 (Blautix), 4.07 (Blautix) were excluded as non-responders. Subjects 3.03 (Blautix) and 3.08 (Placebo) were excluded as methane producers (4.07, mentioned as excluded above, was also a methane producer). Subject 4.09 (Placebo) was excluded due to an aberrant value.

[0144] The results of the corrected hydrogen analysis from the end of the dosing period (day 15/16) were compared to those from the baseline (day 1/2). 10 out of 12 patients (83%) receiving Blautix had a reduction in hydrogen levels over this period (Figure 8a and 8c). In contrast, 3 out of 6 (50%) patients receiving placebo had reduced hydrogen levels (Figure 8b and 8c).

[0145] Figure 9 shows the uncorrected and corrected hydrogen results for the Blautix (Verum) treatment group together with a statistical analysis of the results. The mean values for both uncorrected and corrected H<sub>2</sub> were found to differ between day 1 and day 15. After 13.5 days of treatment, a statistically significant (p < 0.05) decrease of H<sub>2</sub> in Cmax breath test was detected after lactulose stimulation. In contrast, for the placebo group, the mean was found to be equivalent for day 1 and day 15 (p > 0.05) (Figure 10). Thus, the mean for the treatment group (also referred to as the VERUM group), decreases between day 1 and day 15 whereas the mean for the placebo group is equivalent between day 1 and day 15 for both the uncorrected hydrogen results and the corrected hydrogen results (Figure 11).

**Example 7 - Stability testing**

[0146] A composition described herein containing at least one bacterial strain described herein is stored in a sealed container at 25°C or 4°C and the container is placed in an atmosphere having 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90% or 95% relative humidity. After 1 month, 2 months, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years, at least 50%, 60%, 70%, 80% or 90% of the bacterial strain shall remain as measured in colony forming units determined by standard protocols.

**Example 8 - The ability of *B. hydrogenotrophica* to alter the microbiota in human Microbiota Associated rat (HMA rat) model**

**40 Summary**

[0147] Groups of 16 germ-free rats (comprising 8 rats in the control group and 8 rats in the treatment group) were inoculated with the faecal microbiota from a human IBS subject (IBS-HMA rats). Three successive experiments were carried out using faecal samples from 3 different IBS patients. Two other groups of rats (n = 10) were inoculated with faecal samples of healthy subject (n=2 subjects; 2 groups of healthy-HMA rats) as a control. Thus, there were 24 IBS-microbiota associated rats (control), 24 IBS microbiota associated rats treated with Blautix and 20 healthy-microbiota associated rats. Half of the IBS-HMA rats were then administered for 28 days with a composition comprising the bacterial strain of *B. hydrogenotrophica* according to the invention, while the other half animals received a control solution. Day 28 after administration, the levels of microorganisms from faecal microbiota, previously found to be affected in IBS patients was analysed.

**50 Strain**

[0148] *Blautia hydrogenotrophica* (BH) strain DSM 10507<sup>T</sup>/14294.

55

**Composition and administration**

[0149] BH lyophilisate was suspended in sterile mineral solution to a concentration of 10<sup>10</sup> bacteria per ml. Two ml of

this suspension was administered daily per IBS-HMA rat, by oral gavage, for a 28 days period.

[0150] The control solution was the sterile mineral solution that was administered daily (2 ml per rat) by oral gavage to the control group of IBS-HMA rats.

5 Rats

[0151] Germ-Free male Fisher rats (aged 10 weeks) were inoculated with human faecal microbiota from an IBS subject (IBS-HMA rats). Sixteen rats were inoculated with the same human faecal inoculum. Three successive experiments were performed with faecal samples from three different IBS subjects. Two other groups often rats were inoculated with faecal sample from 2 healthy subjects (normo-sensitivity control groups).

10 Study design

[0152] Day -14 - Inoculation of Germ-free rats with human faecal microbiota.

15 Days 0 to 28 - Daily dose of BH lyophilisate (assay group), or control solution (control group) by oral gavage

Days 0, 14 and 28 - Collection of faecal samples for microbial analysis: qPCR for evaluating BH population and other commensal groups of microorganisms and enumeration of functional groups of microorganisms using selective media and strictly anaerobic method.

20 Results

[0153] Figure 12 presents the results of qPCR analysis of the *B. hydrogenotrophica* population in faecal samples from IBS-HMA rats receiving control solution or BH lyophilisate. A significant increase in the BH population was observed at the end of the administration period (D 28) in rats receiving the BH lyophilisate, which confirms successful delivery of BH in the colon.

[0154] Figure 13 reports on effect of administration of *B. hydrogenotrophica* on certain microorganisms in faecal microbiota, previously found to be affected in IBS patients. The level of *Enterobacteriaceae* species decreased after *B. hydrogenotrophica* administration.

30 Conclusions

[0155] Administration of *Blautia hydrogenotrophica* resulted in a reduction in *Enterobacteriaceae*.

35 **Example 9 - Changes in patient symptoms during Phase I clinical trial**

[0156] A Phase I clinical trial was conducted in which *Blautia hydrogenotrophica* ("Blautix", strain deposited under accession number DSM 10507 and also under accession number DSM 14294) was administered to human patients having irritable bowel syndrome (IBS). Patients were administered Blautix during a dosing period (days 1-16) with the washout period being day 19-23. Blautix was found to be both safe and well tolerated. Four symptoms were monitored, of which one was diarrhoea. The study recorded whether patients experienced an improvement in, no change in or worsening of each of these symptoms. Results from patients administered Blautix were compared with those obtained using patients administered a placebo. Symptoms were monitored at three time points: day 1, day 15/16 and at the end of the study. The results are shown in Figures 14 and 15.

[0157] When the patients' reported symptoms at day 16 were compared to the baseline from day 1, 82% of 17 IBS patients receiving Blautix reported an improvement in symptoms (Figure 14). Improvement of symptoms, of which one was diarrhoea, supports the use of Blautix for treating or preventing diarrhoea.

[0158] 50% of patients receiving placebo reported an improvement in symptoms (Figure 14). High placebo response rates are an established phenomenon in IBS clinical studies. Xifaxan was recently approved to treat IBS based on much smaller improvements over placebo (see: <http://www.accessdata.fda.gov/spl/data/5ab6fcbe-4d22-4480-81fc-8bc28c16770d/5ab6fcbe-4d22-4480-81fc-8bc28c16770d.xml>).

[0159] A worsening of symptoms at the study completion (day 19-23) compared to symptoms present upon dosing completion (day 16) is expected based on the teaching presented here. This worsening of symptoms was seen in the Phase I clinical trial: 41% of IBS patients reported worsening of symptoms following cessation of Blautix dosing (Figure 15). The worsening of symptoms, one of which is diarrhoea, following cessation of Blautix dosing therefore also supports the use of Blautix in treating or preventing diarrhoea.

## Sequences

[0160]

5 SEQ ID NO:1 (*Blautia stercoris* strain GAM6-1 16S ribosomal RNA gene, partial sequence - HM626177)

1 tgcaagtcga gcgaagcgc tacgacagaaa cttcggggg aagatgttaa ggactgagcg  
61 gcggacgggt gagtaacgcg tggtaacct gcctcataca gggggataac agttggaaac  
121 ggctgctaat accgcataag cgcacggat cgcatgatac agtgtgaaaa actccggttgg  
181 tatgagatgg acccgcgtct gattagctg ttggaggggt aacggcccac caaggcgacg  
241 atcagtagcc ggcctgagag ggtgaacggc cacattggga ctgagacacg gcccagactc  
301 ctacgggagg cagcagtggg gaatattgca caatgggggaa accctgtatc cagcagcgc  
361 gcgtgaagga agaagtatct cggtatgtaa acttctatca gcagggaga aatgcgggt  
421 acctgactaa gaagccccgg ctaactacgt gccagcagcc gcggtaatac gtagggggca  
481 agcgttatcc ggatttactg ggtgtaaagg gagcgtagac ggaagagcaa gtctgtatgt  
541 aaaggctggg gcttaacccc aggactgcat tggaaactgt ttttcttgag tgccggagag  
601 gtaagcggaa ttcctagtgt agcggtgaaa tgcgtagata ttaggaggaa caccagtggc  
661 gaaggcggct tactggacgg taactgacgt tgaggctcga aagcgtgggg agcaaacagg  
721 attagatacc ctggtagtcc acgcccgtaaa cgatgaatac taggtgttgg ggagcaaagc  
781 tcttcggtgc cgcagcaaac gcaataagta ttccacctgg ggagttacgtt cgcaagaatg  
841 aaactcaaag gaattgacgg ggacccgcac aagcggtgga gcatgtggtt taattcgaag  
901 caacgcgaag aaccttacca agtcttgaca tcgatctgac cggttcgtaa tggAACCTTT  
961 ctttcgggac agagaagaca ggtggtgcat gggttgcgc agctcgtgtc gtgagatgtt  
1021 gggtaagtc ccgcaacgcg cgcacccct atcctcgtatc gccagcaggt aagcgtgggc  
1081 actctgtgga gactgccagg gataacctgg aggaaggcgg ggacgcgtc aaatcatcat  
1141 gccccttatg atttggcgtc cacacgtgtc acaatggcgt aaacaaagg aagcggcc  
1201 gcgggggggaa gcaaatccccaaaataacgt cccagttcggtt actgcgttgc gcaactcgac  
1261 tgcacgaagc tggaaatcgct agtaatcgac aatcagaatg tggcggtgaa tacgttccccg  
1321 ggtcttgcgtac acaccggcccg tcacaccatg ggagtcgtatc acgccccgaag tc

SEQ ID NO:2 (*Blautia wexlerae* strain WAL 14507 16S ribosomal RNA gene, partial sequence - EF036467)

1 caagtgcgaac ggaaattttt ttattgaaac ttcggtcgat ttaatttaat tctagtggcg  
61 gacgggtgag taacgcgtgg gtaacctgcc ttatacaggg ggataacagt cagaaaatggc  
121 tgctaataacc gcataagcgc acagagctgc atggctcagt gtgaaaaact ccgggtggtat  
181 aagatggacc cgcgttggat tagcttggat gtggggtaac ggcccaccaa ggcgacgatc  
241 catagccggc ctgagagggt gaacggccac attgggactg agacacggcc cagactccta  
301 cgggaggcag cagtggggaa tattgcacaa tgggggaaac cctgatgcag cgacgcccgc  
361 tgaaggaaga agtatctcggt tatgtaaact tctatcagca gggaaagatag tgacggtaacc  
421 tgactaagaa gccccggcta actacgtgcc agcagccgc gtaatacgtt gggggcaagc  
481 gttatccgga tttactgggt gtaaaaggag cgttagacggt gtggcaagtc tgatgtgaaa  
541 ggcattggct caacctgtgg actgcattgg aaactgtcat acttgagtgc cggaggggta  
601 agcggattc ctatgttagc ggtgaaatgc gtagatattt ggaggaacac cagtggcgaa  
661 ggcggcttac tggacggtaa ctgacgttga ggctcgaaag cgtggggagc aaacaggatt  
721 agataaccctq qtagtccacq ccqtaaacqa tqaataacta qqtqtcqqqt qgcaaaqcca

781 ttcggtgccg tcgcaaacgc agtaagtatt ccacctgggg agtacgttcg caagaatgaa  
 841 actcaaagga attgacgggg acccgacaa gcggtgagc atgtggta attcgaagca  
 901 acgcgaagaa ccttaccaag tcttgcacatc cgcctgaccg atccttaacc ggatcttcc  
 961 ttcgggacag gcgagacagg tggtgcatgg ttgtcgtcag ctcgtgtcgt gagatgtgg  
 1021 gttaagtccc gcaacgagcg caacccctat cctcagtagc cagcattaa ggtggcact  
 1081 ctggggagac tgccaggat aacctggagg aaggcgggaa tgacgtcaaa tcacatgcc  
 1141 ccttatgatt tgggctacac acgtgctaca atggcgtaaa caaaggaaag cgagattgtg  
 1201 agatggagca aatcccaaaa ataacgtccc agttcggact gtagtctgca acccgactac  
 1261 acgaagctgg aatcgctagt aatcgccgt cagaatgccg cggtaatac gttccgggt  
 1321 cttgtacaca ccgcccgtca caccatggga gtcagtaacg cccgaagtca gtgaccta  
 1381 tgcaaagaag gagctgcccga aggccggacc gatgactgg gtgaagtcgt aacaagggt

SEQ ID NO:3 (consensus 16S rRNA sequence for *Blautia stercoris* strain 830)

20 TTTKGTCGGCTCAGGATGAAACGCTGGCGCGTCTAACACATGCAAGTCGAGCGAAGCGCTTACGACAGAACCTT  
 CGGGGGAAAGATGTAAGGGACTGAGCGCGGACGGGTGAGTAACCGTGGTAACCTGCCCTACACAGGGGATAACA  
 GTTGGAAACGGCTGCTAATACCGATAAGCGCACAGTATCGCATGATAACAGTGTGAAAAACTCCGGTGGTATGAGAT  
 GGACCCGCGTCTGATTAGCTAGTTGGAGGGTAACGCCACCAAGGCGACGATCAGTAGCCGGCTGAGAGGGTGA  
 25 ACGGCCACATTGGGACTGAGACACGGCCAGACTCCTACGGGAGGGCAGCAGTGGGAATATTGACAATGGGGAAA  
 CCCTGATGCAGCGACGCCCGTGAAGGAAGAAGTATCTGGTATGTAAACTTCTATCAGCAGGGAAAGAAAATGACGG  
 TACCTGACTAAGAAGGCCCGGCTAACTACCGTGCAGCAGCCGGTAATACGTAGGGGCAAGCGTTATCCGGATTT  
 ACTGGGTGTAAAGGGAGCGTAGACGGAAGAGCAAGTCTGATGTGAAAGGCTGGGCTTAACCCAGGACTGCATTGG  
 30 AAACTGTTTCTTGAGTGCGGGAGAGGTAAAGCGGAATTCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAA  
 CACCAAGTGGCGAAGGCGGCTTACTGGACGTTACTGACGTTGAGGCTCGAAAGCGTGGGAGCAAACAGGATTAGAT  
 ACCCTGGTAGTCCACGCCGTAAACGATGAAACTAGGGTGTGGGAGCAAAGCTCTCGGTGCCAGCAAACGCAA  
 TAAGTATTCCACCTGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGACCCGACAAGCGTGGAG  
 35 CATGTGGTTATTCGAAGCAACCGGAAGAACCTTACCAAGTCTTGACATCGATCTGACCCTCGTAATGGAACCTT  
 TCCTTCGGGACAGAGAAGACAGGGTGTGCATGGTGTGTCAGCTCGTGTGAGATGTTGGGTAAGTCCCGCAA  
 CGAGCGCAACCCCTATCGTCAGTAGCCAGCGAGGTAAAGCTGGGACTCTGAGGAGACTGCCAGGGATAACCTGGAGG  
 40 AAGGCAGGGACGACGTCAAATCATCATGCCCTTATGATTGGCTACACGTGCTACAATGGCGTAAACAAAGGG  
 AAGCGAGCCCGCAGGGGAGCAAATCCAAAATAACGTCGGACTGCGACTGCAACTCGACTGCACGA  
 AGCTGGAATCGCTAGTAATCGCGAATCAGAATGTCGCGGTGAATACGTTCCGGTCTGTACACACCGCCGTCAC  
 ACCATGGGAGTCAGTAACGCCGAAGTCAGTGACCCAAACCTTAGGGAGGGAGCTGCCAGGCAGGGATTGATAACTG  
 45 GGGTGAAGTCTAGGGGGT

SEQ ID NO:4 (consensus 16S rRNA sequence for *Blautia wexlerae* strain MRX008)

50 TTCATTGAGACTTCGGTGGATTAGATTCTATTCTAGTGGCGGACGGGTGAGTAACCGTGGTAACCTGCCCTAT  
 ACAGGGGGATAACAGTCAGAAATGGCTGCTAATACCGATAAGCGCACAGAGCTGCATGGCTCAGTGTGAAAAACTC  
 CGGTGGTATAAGATGGACCCCGCTGGATTAGCTTGGTGGGTAAACGCCACCAAGGCGACGATCCATAGCCG  
 55 GCCTGAGAGGGTGAACGCCACATTGGGACTGAGACACGGCCAGACTCCTACGGGAGGGCAGCAGTGGGAATATTG  
 CACAATGGGGAAACCTGATGCAGCGACGCCCGTGAAGGAAGAAGTATCTGGTATGTAAACTTCTATCAGCAGG  
 GAAGATAGTGACGGTACCTGACTAAGAAGGCCGGCTAACTACGTGCCAGCGCGGTAAACGTAGGGGGCAAG

CGTTATCCGGATTACTGGGTGTAAAGGGAGCGTAGACGGTGGCAAGTCTGATGTGAAAGGCATGGGCTAACCT  
 GTGGACTGCATTGAAACTGTCATACTTGAGTGCGGAGGGTAAGCGGAATTCTAGTGTAGCGGTGAAATGCGTA  
 GATATTAGGAGGAACACCACTGGCGAAGGCGGCTTACTGGACGTTAAGTGTGAGGCTCGAAAGCGTGGGAGC  
 5 AACAGGATTAGATAACCTGGTAGTCCACGCCGTAACGATGAATACTAGGTGTNGGGAGCATGGCTTCGGTG  
 CCGTCGCAAACGCACTGGAGTACGTTCAAGTAACTCCACCTGGGAGTACGTTCAAGAATGAAACTCAAAGGAATTGACGGGACCC  
 GCACAAGCGGTGGAGCATGTGGTTAATTGAAGCAACGCAAGAACCTTACCAAGTCTGACATCCGCTGACCGA  
 10 TCCTTAACCGATCTTCCTCAGGCGAGACAGGTGGCATGGTTGTCAGCTCGTGTGAGATGTT  
 GGGTTAAGTCCCGCAACGAGCGAACCCCTATCCTCAGTAGGCCAGCATTTAAGGTGGCACTCTGGGAGACTGCCA  
 GGGATAACCTGGAGGAAGGCGGGATGACGTCAAATCATGCCCCTATGATTGGCTACACACGTGCTACAAT  
 GGCATAACAAAGGGAAGCGAGATCGTAGATGGAGCAAATCCAAAATAACGTCCCAGTTGGACTGTAGTCTGC  
 15 AACCCGACTACACGAAGCTGGAATCGCTAGTAATCGGGATCAGAATGCCGGTGAATACGTTCCGGTCTGTG  
 CACACCGCCCGTCACACCATGGGAGTCAGTAACGCCGAAGTCAGTGACCTAACTGCAAAGAAGGAGCTGCCGAA

SEQ ID NO:5 (*Blautia hydrogenotrophica* strain S5a36 16S ribosomal RNA gene, partial sequence - X95624.1)

20 1 gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac gaagcgatacg agaacggaga  
 61 tttcggttga agttttctat tgactgagtg gcggacgggt gagtaacgcg tggtaacct  
 121 gccctataca gggggataac agttagaaat gactgctaatt accgcataag cgcacagctt  
 181 cgcataaggc ggtgtaaaaa actgaggtgg tataaggatgg acccgcggtt gattagctag  
 241 ttggtaggtt aacggccac caaggcgacg atccatagcc ggcctgagag ggtgaacggc  
 301 cacattggga ctgagacacg gcccaaactc ctacgggagg cagcagtggg gaatattgca  
 361 caatggggga aaccctgatg cagcagcgc gcgtgaagga agaagtatct cggatgtaa  
 421 acttctatca gcagggaaaga aagtgcggt acctgactaa gaagccccgg ctaattacgt  
 481 gccagcagcc gcggtaatac gtaagggca acgcgttatcc ggatttactg ggtgtaaagg  
 541 gagcgttagac gggttggcaa gtctgatgtg aaaggcatgg gctcaacctg tggactgcat  
 601 tggaaactgt cagactttagt tgccggagag gcaagcggaa ttcctagtgt agcggtaaaa  
 661 tgcgtagata ttaggaggaa caccagtggc gaaggcggcc tgctggacgg taactgacgt  
 721 tgaggctcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc acgctgtaaa  
 781 ctagataac taggtgtcgg gtggcaaagc cattcggtgc cgcagcaaac gcaataagta  
 841 ttcccacctg gggagtacgt tcgcaagaat gaaactcaaa ggaattgacg gggaccggca  
 901 caagcggtgg agcatgtggt ttaattcgaa gcaacgcgaa gaaccttacc aaatcttgac  
 961 atccctctga cccggaaatgta atgttccctt ttcttcggaa cagaggagac aggtggcga  
 1021 tgggtgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcacgaa ggcacccct  
 1081 tattcttagt agccagcagg tagagctggg cactctagg agactgccag ggataacctg  
 45 1141 gaggaagggt gggatgacgt caaatcatca tgcccttat gattggct acacacgtgc  
 1201 tacaatggcg taaacaaagg gaagcgaagg ggtgacctgg agcaaatttc aaaaataacg  
 1261 tctcagttcg gattgttagtc tgcaactcga ctacatgaag ctgaatcgc tagtaatcgc  
 1321 gaatcagaat gtcgcggta atacgttccc gggcttgta cacaccgccc gtcacaccat  
 1381 gggagtcagt aacgcccggaa gtcagtgacc caaccnaaag gagggagctg ccgaagggtgg  
 1441 gactgataac tgggtgta

## REFERENCES

55 [0161]

[i] Spor et al. (2011) Nat Rev Microbiol. 9(4):279-90.

[ii] Eckburg et al. (2005) *Science*. 10;308(5728):1635-8.

[iii] Tap et al. (2009), *Environ Microbiol*, 11(10):2574-84.

[iv] Macpherson et al. (2001) *Microbes Infect*. 3(12):1021-35

[v] Macpherson et al. (2002) *Cell Mol Life Sci*. 59(12):2088-96.

5 [vi] Mazmanian et al. (2005) *Cell* 15;122(1):107-18.

[vii] Frank et al. (2007) *PNAS* 104(34):13780-5.

[viii] Scanlan et al. (2006) *J Clin Microbiol*. 44(11):3980-8.

[ix] Kang et al. (2010) *Inflamm Bowel Dis*. 16(12):2034-42.

10 [x] Machiels et al. (2013) *Gut*. 63(8):1275-83.

[xi] Lopetuso et al. (2013), *Gut Pathogens*, 5: 23

[xii] WO 2013/050792

[xiii] WO 03/046580

[xiv] WO 2013/008039

15 [xv] WO 2014/167338

[xvi] Lee and Lee (2014) *World J Gastroenterol*. 20(27): 8886-8897.

[xvii] Liu et al. (2008) *Int J Syst Evol Microbiol* 58, 1896-1902.

[xviii] Bernalier et al. (1996) *Arch. Microbiol*. 166 (3), 176-183.

20 [xx] Maşco et al. (2003) *Systematic and Applied Microbiology*, 26:557-563.

[xxi] Srutková et al. (2011) *J. Microbiol. Methods*, 87(1):10-6.

[xxii] Darfeuille-Michaud et al. (2004) *Gastroenterology* 127(2):412-21.

[xxiii] Strus et al. (2015) *Cent Eur J Immunol*.40(4):420-30.

[xxiv] Petersen et al. (2015) *Scand J Gastroenterol*.;50(10):1199-207.

[xxv] Miyamoto-Shinohara et al. (2008) *J. Gen. Appl. Microbiol*., 54, 9-24.

25 [xxvi] Cryopreservation and Freeze-Drying Protocols, ed. by Day and McLellan, Humana Press.

[xxvii] Leslie et al. (1995) *Appl. Environ. Microbiol*. 61, 3592-3597.

[xxviii] Mitropoulou et al. (2013) *JNutr Metab*. (2013) 716861.

[xxix] Kailasapathy et al. (2002) *Curr Issues Intest Microbiol*. 3(2):39-48.

30 [xxx] Handbook of Pharmaceutical Excipients, 2nd Edition, (1994), Edited by A Wade and PJ Weller

[xxxi] Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985)

[xxxii] US 2016/0067188

[xxxiii] Handbook of Microbiological Media, Fourth Edition (2010) Ronald Atlas, CRC Press.

[xxxiv] Maintaining Cultures for Biotechnology and Industry (1996) Jennie C. Hunter-Cevera, Academic Press

[xxxv] Strobel (2009) *Methods Mol Biol*. 581:247-61.

35 [xxxvi] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472.

[xxxvii] Molecular Biology Techniques: An Intensive Laboratory Course, (Ream et al., eds., 1998, Academic Press).

[xxxviii] Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.)

[xxxix] Handbook of Experimental Immunology, Vols. I-IV (D.M. Weir and C.C. Blackwell, eds, 1986, Blackwell Scientific Publications)

40 [xli] Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition (Cold Spring Harbor Laboratory Press).

[xli] Handbook of Surface and Colloidal Chemistry (Birdi, K.S. ed., CRC Press, 1997)

[xlii] Ausubel et al. (eds) (2002) Short protocols in molecular biology, 5th edition (Current Protocols).

[xliii] PCR (Introduction to Biotechniques Series), 2nd ed. (Newton & Graham eds., 1997, Springer Verlag)

45 [xliv] Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987) Supplement 30

[xlv] Smith & Waterman (1981) *Adv. Appl. Math*. 2: 482-489.

## SEQUENCE LISTING

[0162]

50

&lt;110&gt; 4D PHARMA PLC

&lt;120&gt; COMPOSITIONS COMPRISING BACTERIAL STRAINS

55

&lt;130&gt; P068629WO

&lt;141&gt; 2017-07-13

<150> GB 1612190.7  
 <151> 2016-07-13

5 <150> GB 1616018.6  
 <151> 2016-09-20

<150> GB 1616016.0  
 <151> 2016-09-20

10 <150> GB 1703548.6  
 <151> 2017-03-06

<150> GB 1703552.8  
 <151> 2017-03-06

15 <160> 5

<170> SeqWin2010, version 1.0

20 <210> 1  
 <211> 1372  
 <212> DNA  
 <213> Blautia stercoris

25 <400> 1

30	tgcaagtgcg	gcgaagcgct	tacgacagaa	ccttcggggg	aagatgtaa	ggactgagcg	60
	gcggacgggt	gagtaacgcg	tggtaaacct	gcctcataca	gggggataac	agttggaaac	120
	ggctgctaat	accgcataag	cgcacggtat	cgcatac	agtgtaaaa	actccogg	180
	tatgagatgg	acccgcgtct	gattagctag	ttggaggggt	aacggcccac	caaggcgacg	240
	atcagtagcc	ggcctgagag	ggtgaacggc	cacattggga	ctgagacacg	gcccagactc	300
	ctacgggagg	cagcagtggg	aatattgca	caatggggga	aaccctgatg	cagcgacgccc	360
	gcgtgaagga	agaagtatct	cgtatgtaa	acttctatca	gcagggaaaga	aatgacggt	420
	acctgactaa	gaagccccgg	ctaactacgt	gccagcagcc	gcggtataac	gtagggggca	480
35	agcgttatcc	ggatttactg	ggtgtaaagg	gagcgtagac	ggaagagcaa	gtctgatgt	540
	aaaggctggg	gcttaacccc	aggactgcata	tggaaactgt	ttttctttag	tgccggagag	600
	gtaagcggaa	ttccttagtgt	agcggtgaaa	tgcgtagata	ttaggaggaa	caccagtggc	660
	gaaggcggct	tactggacgg	taactgacgt	tgaggctcga	aagcgtgggg	agcaaacagg	720
	attagatacc	ctggtagtcc	acggcgtaaa	cgatgaatac	taggtgttgg	ggagcaaagc	780
40	tcttcgggtc	cgcagcaaac	gcaataagta	ttccacctgg	ggagtacgtt	cgcaagaatg	840
	aaactcaaag	gaattgacgg	ggacccgcac	aagcgttga	gcatgtggtt	taattcgaag	900
	caacgcgaag	aaccttacca	agtcttgaca	tcgatctgac	cggttcgtta	tggAACCTTT	960
	ccttcgggac	agagaagaca	ggtgttgcat	ggttgtcg	agtcgtgtc	gtgagatgtt	1020
	gggttaagtc	ccgcaacagag	cgcaacccct	atcctcagta	gccagcaggt	gaagctggc	1080
45	actctgtgga	gactgccagg	gataaacctgg	aggaaggcgg	ggacgacgtc	aaatcatcat	1140
	gccccttatg	atttgggcta	cacacgtgct	acaatggcgt	aaacaaaggg	aagcgagccc	1200
	gcgagggggg	gcaaatccca	aaaataacgt	cccagttcg	actgcagtct	gcaactcgac	1260
	tgcacgaagc	tggaatcgct	agtaatcgct	aatcagaatg	tcgcggtaa	tacgttccc	1320
	ggtcttgtac	acaccgcccc	tcacaccatg	ggagtca	acgccccgaag	tc	1372
50	<210> 2 <211> 1438 <212> DNA <213> Blautia wexlerae						
55	<220> <221> n <222> 19 <223> 'n' is a, c, g or t						

<400> 2

5	caagtgcgaac	gggaattant	ttattgaaac	ttcggtcgat	ttaatttaat	tctagtggcg	60
	gacgggtgag	taacgcgtgg	gtaacacctgc	ttatacaggg	ggataacagt	cagaaatggc	120
	tgctaataacc	gcataagcgc	acagagctgc	atggctcagt	gtgaaaaact	ccggtgttat	180
	aagatggacc	cgcgttggat	tagttgttgc	gtggggtaac	ggcccaccaa	ggcgaacgatc	240
	catagccggc	ctgagaggggt	gaacggccac	attgggactg	agacacggcc	cagactccta	300
	cgggaggcag	cagtggggaa	tattgcacaa	tggggaaac	cctgatgcag	cgacgcgcg	360
10	tgaaggaaga	agtatctcg	tatgtaaact	tctatcagca	gggaagatag	tgacggtacc	420
	tgactaagaa	gccccggcta	actacgtgcc	agcagccgcg	gtaatacgt	gggggcaagc	480
	gttatccgga	tttactgggt	gtaaaggggag	cgtagacggt	gtggcaagt	tgatgtgaaa	540
	ggcatgggct	caacctgtgg	actgcattgg	aaactgtcat	acttgagtgc	cggaggggta	600
	agcggaaattc	ctagtgttagc	ggtaaatgc	gtagatatta	ggaggaacac	cagtggcgaa	660
	ggcggcttac	tggacggtaa	ctgacgttga	ggctcgaaag	cgtggggagc	aaacaggatt	720
15	agataaccctg	gtagtccacg	ccgtaaacga	tgaataacta	ggtgtcggt	ggcaaagcca	780
	ttcgggtcccg	tcgcaaacgc	agtaagtatt	ccacctgggg	agtacgttcg	caagaatgaa	840
	actcaaagga	attgacgggg	accggcacaa	gcggtgaggc	atgtggttt	attcgaagca	900
	acgcgaagaa	ccttaccaag	tcttgacatc	cgcctgaccg	atcctaacc	ggatcttcc	960
	ttcgggacag	gcgagacagg	tggtgcattgg	ttgtcgctag	ctcggtcg	gagatgttgg	1020
	gttaagtccc	gcaacgagcg	caacccctat	cctcagtagc	cagcattaa	ggtgggcact	1080
20	ctggggagac	tgccagggt	aacctggagg	aaggcgggga	tgacgtcaaa	tcatcatgcc	1140
	ccttatgatt	tgggctacac	acgtgtaca	atggcgtaaa	caaagggaaag	cgagattgtg	1200
	agatggagca	aatcccaaaa	ataacgtccc	agttcggact	gtagtctgca	acccgactac	1260
	acgaagctgg	aatcgctag	aatcgcggat	cagaatgccc	cggtgaatac	gttcccgggt	1320
	cttgcataaca	ccgccccgtca	caccatggga	gtcagtaacg	cccgaaagtca	gtgacctaac	1380
25	tgcaaagaag	gagctgccga	aggcggggacc	gatgactggg	gtgaagtgcgt	aacaaggt	1438

<210> 3

<211> 1481

<212> DNA

30 <213> Blautia stercoris

<220>

<221> k

<222> 4

35 <223> k is q or t

<400> 3

40	tttktgtctgg ctcaggatga acgctggcg gcttacgaca gaacttcgg gggaaagatgt gcgtggtaa cctgcctcat acagggggat aagcgcacag tatcgcatga tacagtgtga tctgattagc tagttggagg ggtAACGCC gagggtgaac ggccacattg ggactgagac ggggaatatt gcacaatggg ggaaaccctg tctcggtatg taaacttcta tcagcaggga cggctaacta cgtgccagca gcccggtaa ctgggtgtaa agggagcgta gacggaagag cccaggactg cattggaaac tgTTTTCTT tgtagcggtg aaatgcgtag atattaggag cggtaactga cgttgggct cgaaagcgtg tccacgcccgt aaacgatgaa tactaggtgt aacgcaataa gtattccacc tggggagtac cggggaccccg cacaaggcgt ggagcatgtg caagtcttga catcgatctg accgggtcgt caggtggtgc atgggtgtcg tcagctcgtg agcgcacccctatcgtcgt tagccagcag qqqataaccc qqqqaaaggc qqqqacqacq	cgtgcttaac acatgcaagt cgagcgaagc gcttacgaca gaacttcgg gggaaagatgt aagggactga gcggcggacg ggtgagtaac gcgtggtaa cctgcctcat acagggggat aacagttgga aacggctgct aataccgcat aagcgcacag tatcgcatga tacagtgtga aaaactccgg tggtatgaga tggaccgcg tctgattagc tagttggagg ggtAACGCC caccaggcg acgatcaga gcccggctga gagggtgaac ggccacattg ggactgagac acggcccaaga ctctacggg aggccagcgt ggggaatatt gcacaatggg ggaaaccctg atgcagcgcac gccgcgtgaa ggaagaagta tctcggtatg taaacttcta tcagcaggga agaaaatgac ggtacctgac taagaagccc cggctaacta cgtgccagca gcccggtaa tacgtagggg gcaagcgtta tccggattta ctgggtgtaa agggagcgta gacggaagag caagtctgtat gtgaaaaggct ggggcttaac cccaggactg cattggaaac tgTTTTCTT gagtgccggg gaggtaagcg gaattcttag tgtagcggtg aaatgcgtag atattaggag gagtgccggg gaggtaagcg gaattcttag cggtaactga cgttgggct cgaaagcgtg gggagcaaac aggattagat accctggtag tccacgcccgt aaacgatgaa tactaggtgt tggggagcaa agtcttcgg tgccgcagca aacgcaataa gtattccacc tggggagtac gttcgcaaga atgaaactca aaggaattga cggggaccccg cacaaggcgt ggagcatgtg gtttattcga agcaacgcga agaacccattac caagtcttga catcgatctg accgggtcgt aatggaaacct ttcttcggg acagagaaga caggtggtgc atgggtgtcg tcgtgagatg ttgggttaag tcccgcaacg agcgcacccctatcgtcgt tagccagcag gtaaaagctgg qcactctgag gagactgcca qqqataaccc qqqqaaaggc qqqqacqacq tcaaatcatc atqccccctta tqattttggqc	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200
45			
50			
55			

5	tacacacgtg ctacaatggc gtaaacaag ggaagcgagc ccgcgagggg gagcaaatcc	1260
	caaaaataac gtcccagttc ggactgcagt ctgcaactcg actgcacgaa gctggaatcg	1320
	ctagtaatcg cgaatcagaa tgtcgcggtg aatacgttcc cgggtcttgc acacaccgccc	1380
	cgtcacacca tgggagtcag taacgcccga agtcagtgac ccaaccttag ggagggagct	1440
	gccgaaggcg ggattgataa ctggggtgaa gtctaggggg t	1481

10 <210> 4  
 <211> 1384  
 <212> DNA  
 <213> Blautia wexlerae

15 <220>  
 <221> n  
 <222> 749  
 <223> 'n' is a, c, g or t

<400> 4

20	ttcattgaga cttcggtgga tttagattct atttcttagtg gcggacgggt gagtaacqcg	60
	tggtaacct gccttataca ggggataaac agtcagaaat ggctgctaat accgcataag	120
	cgcacagagc tgcattggctc agtgtgaaaa actccgggttataagatgg acccgcgttg	180
	gattagctt gttgggggt aacggccac caaggcagac atccatagcc ggcctgagag	240
	ggtaaacggc cacattgggatcctgagacacg gcccagactc ctacgggagg cagcagtggg	300
	gaatattgca caatggggaa aaccctgtatcgcagcggaa aaccctgtatcgcagcggaa	360
25	cgttatgtaa acttctatca gcaaggaa aaccctgtatcgcagcggaa aaccctgtatcgcagcggaa	420
	ctaactacgt gccagcagcc gcgtaatac gttagggggca agcgttatcc ggattactg	480
	ggttaaagg gagcgttagac ggtgtggcaa gtctgatgtg aaaggcatgg gctcaacctg	540
	tggactgcat tggaaactgt cataactttagtgcgttagata ttaggaggaa caccagtggc	600
	agcgtgaaa tgcgttagata ttaggaggaa caccagtggc gaaggcggct tactggacgg	660
30	taactgacgt tgaggctcga aagcgtgggg agcaaacagg attagataacc ctggtagtcc	720
	acgcctgtaaa cgatgaataac taggtgtcng gggagcatgg ctcttcgggt ccgtogcaaa	780
	cgcagtaagt attccacctg gggagttacgt tcgcaagaat gaaactcaaa ggaattgacg	840
	gggacccgca caagcggtgg agcatgtgg ttaattcgaa gcaacgcgaa gaaccttacc	900
	aagtcttgac atccgcctga ccgtatccta accggatctt tccttcgggaa caggcggagac	960
35	aggtggtgca tgggtgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga	1020
	gcgcaaccccc tatcctcaagt agccagcatt taaggtggc actctgggg aactgcccagg	1080
	gataacctgg aggaaggccgg ggatgacgtc aaatcatcat gcccctttag atttgggcta	1140
	cacacgtgct acaatggcgt aaacaaaggaa aagcggatc gtgagatgg gcaaatcccc	1200
	aaaataacgt cccagttcgg actgtgtct gcaacccgac tacacgaagc tggaaatcgct	1260
40	agtaatcgcg gatcagaatg ccgcgggtgaa tacgttcccg ggtcttgcgtac acaccggcccg	1320
	tcacaccatg ggagttagtgcgtac acgcggcgtac tcagtgcgtact aactgcaag aaggagatgc	1380
	cgaa	1384

45 <210> 5  
 <211> 1458  
 <212> DNA  
 <213> Blautia hydrogenotrophica

50 <220>  
 <221> n  
 <222> 1416  
 <223> 'n' is a, c, g or t

<400> 5

5	gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac gaagcgatacg agaacggaga 60 tttcgggtga agttttctat tgactgagtg gcggacgggt gagtaacgcg tggtaacct 120 gcccataca gggggataac agtagaaat gactgtaat accgcataaag cgcacagctt 180 cgcatgaagc ggtgtaaaaa actgaggtgg tataggatgg acccgcgtt gattagctag 240 tttgtgaggt aacggccac caaggcgcacg atccatagcc ggcctgagag ggtgaacggc 300 cacattggga ctgagacacg gcccaaactc ctacgggagg cagcagtggg gaatattgca 360 caatggggga aaccctgatg cagcgcacgccc gcgtgaagga agaagtatct cggtatgtaa 420 acttctatca gcagggaaaga aagtgcacgtt acctgactaa gaagccccgg ctaattacgt 480 gccagcagcc gcggtaataac gtaaggggca agcgttatcc ggatttactg ggtgtaaagg 540 gagcgttagac ggtttggcaa gtctgatgtg aaaggcatgg gctcaacctg tggactgcat 600
10	
15	tggaaactgt cagacttgag tgccggagag gcaaggcgaa ttcttagtgc agcggtgaaa 660 tgcgtagata ttaggagaa caccagtggc gaaggcggcc tgctggacgg taactgacgt 720 tgaggctcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc acgctgtaaa 780 cgatgaatac taggtgtcgg gtggcaaagc cattcgggtgc cgcagcaac gcaataagta 840 ttcccacctg gggagtagtgc tcgcaagaat gaaactcaaa ggaattgacg gggacccgca 900 caagcggtgg agcatgtggg ttaattcgaa gcaacgcgaa gaaccttacc aaatcttgac 960 atccctctga ccggaaagta atgttccctt ttcttcggaa cagaggagac aggtggtgca 1020 20 tggtgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacgca gcgcaaccct 1080 tattcttagt agccagcagg tagagctggg cactctaggg agactgcccag ggataaacctg 1140 gaggaaggtg gggatgacgt caaatcatca tgccccttat gatttgggctt acacacgtgc 1200 tacaatggcg taaacaaaagg gaagcgaagg ggtgacctgg agcaaatctc aaaaataacg 1260 tctcagttcg gattgttagtc tgcaactcga ctacatgaag ctggaaatcgc tagtaatcgc 1320 25 gaatcagaat gtgcgggtga atacgttccc ggtcttgta cacaccgccc gtcacaccat 1380 gggagtcagt aacgccccgaa gtcagtgacc caaccnaaag gaggagctg ccgaagggtgg 1440 gactgataac tgggggtga 1458
20	
25	

### Claims

1. A composition comprising a bacterial strain of the genus *Blautia hydrogenotrophica* having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, for use in a method of reducing the level of pathogenic *Enterobacteriaceae* in the gastrointestinal tract.
- 35 2. The composition for use of claim 1, wherein the *Enterobacteriaceae* is *E. coli*.
3. The composition for use of claim 1 or claim 2, wherein the composition is for use in a method of reducing the level of *Enterobacteriaceae* in the gastrointestinal tract in the treatment or prevention of IBS, Crohn's disease, ulcerative colitis, functional dyspepsia, diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis.
- 40 4. The composition for use of claim 1 or claim 2, wherein the composition is for use in treating or preventing diarrhoea, gastroenteritis, urinary tract infection or neonatal meningitis.
5. A composition comprising a bacterial strain of the genus *Blautia hydrogenotrophica* having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, for use in the treatment of infections caused by pathogenic *Enterobacteriaceae* in the gastrointestinal tract.
- 45 6. The composition for use of claim 5, wherein the infection caused by pathogenic *Enterobacteriaceae* is an *E. coli* infection.
7. The composition for use of any preceding claim, wherein the bacterial strain has a 16s rRNA sequence that is at least 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5 or which has the 16s rRNA sequence of SEQ ID NO:5.
- 50 8. The composition for use of claim 1, wherein the composition comprises a bacterial strain of the species *Blautia hydrogenotrophica* having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, for use in a method of reducing the level of pathogenic *Enterobacteriaceae* in the gastrointestinal tract in a subject diagnosed with IBS.
9. The composition for use of any preceding claim, wherein the composition is for oral administration.

10. The composition for use of any preceding claim, wherein the composition comprises one or more pharmaceutically acceptable excipients or carriers.
11. The composition for use of any preceding claim, wherein the bacterial strain is lyophilised.
- 5 12. The composition for use of any preceding claim, wherein the bacterial strain is viable.
13. The composition for use of any preceding claim, wherein the composition comprises a single strain.
- 10 14. The composition for use of any preceding claim, which comprises the *Blautia hydrogenotrophica* bacterial strain as part of a microbial consortium.
15. A food product comprising the composition of any preceding claim, for the use of any preceding claim.

15 **Patentansprüche**

1. Zusammensetzung, umfassend einen Bakterienstamm der Gattung *Blautia hydrogenotrophica* mit einer 16s-rRNA-Sequenz, die mindestens 95% identisch zu SEQ ID NO: 5 ist, zur Verwendung bei einem Verfahren zum Reduzieren des Gehalts an pathogenen *Enterobacteriaceae* im Magen-Darm-Trakt.
2. Zusammensetzung zur Verwendung nach Anspruch 1, wobei die *Enterobacteriaceae E. coli* sind.
3. Zusammensetzung zur Verwendung nach Anspruch 1 oder Anspruch 2, wobei die Zusammensetzung zur Verwendung bei einem Verfahren zum Reduzieren des Gehalts an *Enterobacteriaceae* im Magen-Darm-Trakt bei der Behandlung oder Prävention von IBS, Morbus Crohn, Colitis ulcerosa, funktioneller Dyspepsie, Diarrhoe, Gastroenteritis, Harnwegsinfektion oder Meningitis bei Neugeborenen vorgesehen ist.
4. Zusammensetzung zur Verwendung nach Anspruch 1 oder Anspruch 2, wobei die Zusammensetzung zur Verwendung bei der Behandlung oder Prävention von Diarrhoe, Gastroenteritis, Harnwegsinfektion, Meningitis bei Neugeborenen vorgesehen ist.
5. Zusammensetzung, umfassend einen Bakterienstamm der Gattung *Blautia hydrogenotrophica* mit einer 16s-rRNA-Sequenz, die mindestens 95% identisch zu SEQ ID NO: 5 ist, zur Verwendung bei der Behandlung von Infektionen, die durch pathogene *Enterobacteriaceae* im Magen-Darm-Trakt verursacht werden.
6. Zusammensetzung zur Verwendung nach Anspruch 5, wobei die durch pathogene *Enterobacteriaceae* verursachte Infektion eine *E. coli*-Infektion ist.
7. Zusammensetzung zur Verwendung nach einem vorhergehenden Anspruch, wobei der Bakterienstamm eine 16s-rRNA-Sequenz hat, die mindestens 97%, 98%, 99%, 99,5% oder 99,9% identisch zu SEQ ID NO: 5 ist oder die die 16s-rRNA-Sequenz von SEQ ID NO: 5 hat.
8. Zusammensetzung zur Verwendung nach Anspruch 1, wobei die Zusammensetzung einen Bakterienstamm der Art *Blautia hydrogenotrophica* mit einer 16s-rRNA-Sequenz umfasst, die mindestens 95% identisch zu SEQ ID NO: 5 ist, zur Verwendung bei einem Verfahren zum Reduzieren des Gehalts an *Enterobacteriaceae* im Magen-Darm-Trakt bei einem Individuum, bei dem IBS diagnostiziert wurde.
9. Zusammensetzung zur Verwendung nach einem vorhergehenden Anspruch, wobei die Zusammensetzung zur oralen Verabreichung vorgesehen ist.
10. Zusammensetzung zur Verwendung nach einem vorhergehenden Anspruch, wobei die Zusammensetzung einen oder mehr pharmazeutisch akzeptable Exzipienten oder Träger umfasst.
- 55 11. Zusammensetzung zur Verwendung nach einem vorhergehenden Anspruch, wobei der Bakterienstamm lyophilisiert ist.
12. Zusammensetzung zur Verwendung nach einem vorhergehenden Anspruch, wobei der Bakterienstamm lebensfähig

ist.

13. Zusammensetzung zur Verwendung nach einem vorhergehenden Anspruch, wobei die Zusammensetzung einen einzelnen Stamm umfasst.

5 14. Zusammensetzung zur Verwendung nach einem vorhergehenden Anspruch, die den *Blautiahydrogenotrophica*-Bakterienstamm als Teil eines mikrobiellen Konsortiums umfasst.

10 15. Nahrungsmittelprodukt, umfassend die Zusammensetzung nach einem vorhergehenden Anspruch zur Verwendung nach einem vorhergehenden Anspruch.

### Revendications

15 1. Composition comprenant une souche bactérienne du genre *Blautia hydrogenotrophica* ayant une séquence d'ARNr 16s qui est au moins 95 % identique à SEQ ID NO: 5, pour utilisation dans un procédé de réduction du taux d'*Enterobacteriaceae* pathogène dans le tractus gastro-intestinal.

20 2. Composition pour utilisation selon la revendication 1, dans laquelle l'*Enterobacteriaceae* est *E. coli*.

3. Composition pour utilisation selon la revendication 1 ou la revendication 2, la composition étant pour utilisation dans un procédé de réduction du taux d'*Enterobacteriaceae* dans le tractus gastro-intestinal dans le traitement ou la prévention de MII, la maladie de Crohn, la recto-colite hémorragique, la dyspepsie fonctionnelle, la diarrhée, la gastro-entérite, une infection des voies urinaires ou la méningite néonatale.

25 4. Composition pour utilisation selon la revendication 1 ou la revendication 2, la composition étant pour utilisation dans le traitement ou la prévention de la diarrhée, la gastro-entérite, une infection des voies urinaires ou la méningite néonatale.

30 5. Composition comprenant une souche bactérienne du genre *Blautia hydrogenotrophica* ayant une séquence d'ARNr 16s qui est au moins 95 % identique à SEQ ID NO: 5, pour utilisation dans le traitement d'infections causées par des *Enterobacteriaceae* pathogènes dans le tractus gastro-intestinal.

35 6. Composition pour utilisation selon la revendication 5, l'infection causée par une *Enterobacteriaceae* pathogène étant une infection par *E. coli*.

7. Composition pour utilisation selon l'une quelconque des revendications précédentes, dans laquelle la souche bactérienne a une séquence d'ARNr 16s qui est au moins 97 %, 98 %, 99 %, 99,5 % ou 99,9 % identique à SEQ ID NO: 5 ou qui a la séquence d'ARNr 16s de SEQ ID NO: 5.

40 8. Composition pour utilisation selon la revendication 1, la composition comprenant une souche bactérienne de l'espèce *Blautia hydrogenotrophica* ayant une séquence d'ARNr 16s qui est au moins 95 % identique à SEQ ID NO: 5, pour utilisation dans un procédé de réduction du taux d'*Enterobacteriaceae* dans le tractus gastro-intestinal chez un sujet diagnostiqué avec MII.

45 9. Composition pour utilisation selon l'une quelconque des revendications précédentes, la composition étant pour administration orale.

10. Composition pour utilisation selon l'une quelconque des revendications précédentes, la composition comprenant un ou plusieurs excipients ou véhicules pharmaceutiquement acceptables.

50 11. Composition pour utilisation selon l'une quelconque des revendications précédentes, dans laquelle la souche bactérienne est lyophilisée.

12. Composition pour utilisation selon l'une quelconque des revendications précédentes, la souche bactérienne étant viable.

55 13. Composition pour utilisation selon l'une quelconque des revendications précédentes, la composition comprenant

une souche unique.

**14.** Composition pour utilisation selon l'une quelconque des revendications précédentes, qui comprend la souche bactérienne de *Blautia hydrogenotrophica* en tant que partie d'un consortium microbien.

5

**15.** Produit alimentaire comprenant la composition selon l'une quelconque des revendications précédentes, pour l'utilisation selon l'une quelconque des revendications précédentes.

10

15

20

25

30

35

40

45

50

55

**FIG. 1**  
**Measurement of BH population by q-PCR**





FIG. 2



**FIG. 3**  
Wash out period




FIG. 4




FIG. 6






FIG. 5








FIG. 7b

□ Enterobacteria Day 1 □ Enterobacteria Day 16 □ Enterobacteria EOS


**FIG. 8a** Blautix 10/12 show reduction in hydrogen (83%)

Patient ID	DAY 1	DAY 2	MEAN	DAY 15	DAY 16	MEAN	DIFF
	CMAX	CMAX	CMAX	CMAX	CMAX	CMAX	CMAX
3.02	123.0	94.0	108.5	34.0	74.0	54.0	-54.5
3.04	70.0	32.0	51.0	25.0	46.0	35.5	-15.5
3.05	163.0	116.0	139.5	167.0	111.0	139.0	-0.5
3.07	71.0	69.0	70.0	46.0	80.0	63.0	-7.0
3.09	121.0	76.0	98.5	66.0	65.0	65.5	-33.0
3.11	75.0	98.0	86.5	128.0	76.0	102.0	15.5
3.13	118.0	41.0	79.5	85.0	59.0	72.0	-7.5
3.15	155.0	99.0	127.0	63.0	87.0	75.0	-52.0
3.17	134.0	210.0	172.0	138.0	107.0	123.0	-49.0
3.19	72.0	53.0	62.5	87.0	85.0	86.0	23.5
3.21	144.0	139.0	141.5	75.0	126.0	100.5	-41.0
3.22	59.0	71.0	65.0	55.0	34.0	44.5	-20.5
Patients with reduction in H <sub>2</sub> 10 (83%)							
Mean	108.8	91.5	100.1	80.8	79.2	80.0	-20.1
SD	37.3	48.4		43.5	26.7		26.2
Median	119.5	85.0		70.5	78.0		-18.0

**FIG. 8b** Placebo 3/6 show reduction in hydrogen (50%)


PatientID	DAY 1		DAY 2		MEAN		DAY 15		DAY 16		MEAN		DIFF CMAX
	CMAX	CMAX	CMAX	CMAX	CMAX	CMAX							
3.06	126.0	91.0	108.5	108.5	86.0	131.0	108.5	108.5	108.5	108.5	108.5	108.5	0.0
3.10	124.0	163.0	146.0	146.0	107.0	88.0	97.5	97.5	97.5	97.5	97.5	97.5	-48.5
3.14	55.0	79.0	67.0	67.0	53.0	68.0	60.5	60.5	60.5	60.5	60.5	60.5	-6.5
3.16	98.0	123.0	110.5	110.5	123.0	151.0	137.0	137.0	137.0	137.0	137.0	137.0	26.5
3.23	53.0	113.0	85.5	85.5	79.0	99.0	89.0	89.0	89.0	89.0	89.0	89.0	3.5
4.13	59.0	69.0	63.5	63.5	25.0	36.0	31.5	31.5	31.5	31.5	31.5	31.5	-32.0
MEAN	86.5	107.2	96.8	96.8	78.8	95.8	87.3	87.3	87.3	87.3	87.3	87.3	-9.5
SD	33.8	36.0	31.2	31.2	35.7	41.2	37.0	37.0	37.0	37.0	37.0	37.0	26.8
MEDIAN	78.0	102.0	97.0	97.0	82.5	93.5	93.3	93.3	93.3	93.3	93.3	93.3	-3.3
													3 (50%)

**FIG. 8c**




VERUM group	DAY 1		DAY 15		H2 Corrected		RANDOM		DAY 1		DAY 15	
	RANDOM	NUMBER	CMAX	CMAX	NUMBER	CMAX	NUMBER	CMAX	NUMBER	CMAX	NUMBER	CMAX
3.02	89.8	23.0			3.02	123.0						
3.04	63.0	21.0			3.04	70.0						
3.05	130.4	112.8			3.05	163.0						
3.07	56.8	37.6			3.07	71.0						
3.09	96.8	52.8			3.09	121.0						
3.11	63.0	104.9			3.11	75.0						
3.12	12.3	38.7			3.12	16.0						
3.13	110.3	82.5			3.13	118.0						
3.15	112.7	53.8			3.15	155.0						
3.17	97.8	83.7			3.17	134.0						
3.19	51.1	66.1			3.19	72.0						
3.21	144.0	71.4			3.21	144.0						
3.22	52.7	43.9			3.22	59.0						
3.24	27.1	26.7			3.24	29.0						
	T Test unilateral		0.02032643		T Test unilateral		0.04798555					

**FIG. 9b**  
**Hydrogen uncorrected**



**FIG. 9c**  
**Hydrogen corrected**




## PLACEBO Group


NUMBER	DAY1		DAY15		H2 corrected		RANDOM		DAY1		DAY15	
	MAX	CMAX	MAX	CMAX	NUMBER	CMAX	NUMBER	CMAX	MAX	CMAX	MAX	CMAX
3.06	103.3	81.9			3.06		126.0		86.0			
3.08	42.3	43.3			3.08		55.0		58.0			
3.10	97.6	84.3			3.10		124.0		107.0			
3.14	35.0	42.4			3.14		55.0		53.0			
3.16	59.0	80.9			3.16		98.0		123.0			
3.21	41.1	62.2			3.21		58.0		79.0			
4.13	53.2	25.0			4.13		58.0		25.0			
	T Test unilateral	0.41620669							T Test unilateral	0.27096549		
	DAY1	DAY15							DAY1	DAY15		
	MEAN	61.7	60.0						MEAN	82.0	75.9	
	SD	27.7	23.5						SD	33.1	33.5	
	N	7	7						N	7	7	
	MEDIAN	53.2	62.2						MEDIAN	58.0	79.0	
	MN	35.0	25.0						MN	55.0	25.0	
	MAX	103.3	84.3						MAX	126.0	123.0	



FIG. 10a

**FIG. 10b**  
Hydrogen uncorrected placebo



**FIG. 10c**  
Hydrogen corrected placebo



**FIG. 11a****FIG. 11b**



**FIG. 12****FIG. 13**

FIG. 14





FIG. 15



## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- WO 0185187 A [0004]
- US 20100247489 A [0006]
- WO 2016086206 A [0007]
- WO 2012142605 A [0008]
- WO 2013050792 A [0161]
- WO 03046580 A [0161]
- WO 2013008039 A [0161]
- WO 2014167338 A [0161]
- US 20160067188 A [0161]
- GB 1612190 A [0162]
- GB 1616018 A [0162]
- GB 1616016 A [0162]
- GB 1703548 A [0162]
- GB 1703552 A [0162]

## Non-patent literature cited in the description

- **SPOR et al.** *Nat Rev Microbiol.*, 2011, vol. 9 (4), 279-90 [0161]
- **ECKBURG et al.** *Science*, 2005, vol. 10;308 (5728), 1635-8 [0161]
- **TAP et al.** *Environ Microbiol*, 2009, vol. 11 (10), 2574-84 [0161]
- **MACPHERSON et al.** *Microbes Infect.*, 2001, vol. 3 (12), 1021-35 [0161]
- **MACPHERSON et al.** *Cell Mol Life Sci.*, 2002, vol. 59 (12), 2088-96 [0161]
- **MAZMANIAN et al.** *Cell*, 2005, vol. 15;122 (1), 107-18 [0161]
- **FRANK et al.** *PNAS*, 2007, vol. 104 (34), 13780-5 [0161]
- **SCANLAN et al.** *J Clin Microbiol.*, 2006, vol. 44 (11), 3980-8 [0161]
- **KANG et al.** *Inflamm Bowel Dis.*, 2010, vol. 16 (12), 2034-42 [0161]
- **MACHIELS et al.** *Gut*, 2013, vol. 63 (8), 1275-83 [0161]
- **LOPETUSO et al.** *Gut Pathogens*, 2013, vol. 5, 23 [0161]
- **LEE ; LEE.** *World J Gastroenterol.*, 2014, vol. 20 (27), 8886-8897 [0161]
- **LIU et al.** *Int J Syst Evol Microbiol*, 2008, vol. 58, 1896-1902 [0161]
- **BERNALIER et al.** *Arch. Microbiol.*, 1996, vol. 166 (3), 176-183 [0161]
- **MASCO et al.** *Systematic and Applied Microbiology*, 2003, vol. 26, 557-563 [0161]
- **SRUTKOVÁ et al.** *J. Microbiol. Methods*, 2011, vol. 87 (1), 10-6 [0161]
- **DARFEUILLE-MICHAUD et al.** *Gastroenterology*, 2004, vol. 127 (2), 412-21 [0161]
- **STRUS et al.** *Cent Eur J Immunol.*, 2015, vol. 40 (4), 420-30 [0161]
- **PETERSEN et al.** *Scand J Gastroenterol.*, 2015, vol. 50 (10), 1199-207 [0161]
- **MIYAMOTO-SHINOHARA et al.** *J. Gen. Appl. Microbiol.*, 2008, vol. 54, 9-24 [0161]
- Cryopreservation and Freeze-Drying Protocols. *Humana Press* [0161]
- **LESLIE et al.** *Appl. Environ. Microbiol.*, 1995, vol. 61, 3592-3597 [0161]
- **MITROPOULOU et al.** *J Nutr Metab.*, 2013, 716861 [0161]
- **KAILASAPATHY et al.** *Curr Issues Intest Microbiol.*, 2002, vol. 3 (2), 39-48 [0161]
- Handbook of Pharmaceutical Excipients. 1994 [0161]
- Remington's Pharmaceutical Sciences. Mack Publishing Co, 1985 [0161]
- **RONALD ATLAS.** *Handbook of Microbiological Media*. CRC Press, 2010 [0161]
- **JENNIE C. HUNTER-CEVERA.** *Maintaining Cultures for Biotechnology and Industry*. Academic Press, 1996 [0161]
- **STROBEL.** *Methods Mol Biol.*, 2009, vol. 581, 247-61 [0161]
- **GENNARO.** *Remington: The Science and Practice of Pharmacy*. 2000 [0161]
- Molecular Biology Techniques: An Intensive Laboratory Course. Academic Press, 1998 [0161]
- Methods In Enzymology. Academic Press, Inc, [0161]
- Handbook of Experimental Immunology. Blackwell Scientific Publications, 1986, vol. I-IV [0161]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 2001 [0161]
- Handbook of Surface and Colloidal Chemistry. CRC Press, 1997 [0161]
- Short protocols in molecular biology. *Current Protocols*, 2002 [0161]
- Introduction to Biotechniques Series. PCR. Springer Verlag, 1997 [0161]

**EP 3 313 421 B1**

- Current Protocols in Molecular Biology. 1987 [0161]
- **SMITH ; WATERMAN.** *Adv. Appl. Math.*, 1981, vol. 2, 482-489 [0161]